EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
S1	791	(546/114).CCLS.	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2006/03/08 13:24
S2	600	(514/301).CCLS.	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2006/03/08 13:24
S10	2	("200128993").PN.	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2006/03/08 13:25

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1600RXA

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	DEC 05	CASREACT(R) - Over 10 million reactions available
NEWS 4	DEC 14	2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS 5	DEC 14	2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS 6	DEC 14	CA/CAplus to be enhanced with updated IPC codes
NEWS 7	DEC 21	IPC search and display fields enhanced in CA/CAplus with the IPC reform
NEWS 8	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/ USPAT2
NEWS 9	JAN 13	IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 10	JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS 11	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS 12	JAN 17	IPC 8 in the WPI family of databases including WPIFV
NEWS 13	JAN 30	Saved answer limit increased
NEWS 14	JAN 31	Monthly current-awareness alert (SDI) frequency added to TULSA
NEWS 15	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS 16	FEB 22	Status of current WO (PCT) information on STN
NEWS 17	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS 18	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS 19	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS 20	FEB 28	MEDLINE/LMEDLINE reload improves functionality
NEWS 21	FEB 28	TOXCENTER reloaded with enhancements
NEWS 22	FEB 28	REGISTRY/ZREGISTRY enhanced with more experimental spectral property data
NEWS 23	MAR 01	INSPEC reloaded and enhanced
NEWS 24	MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT
http://download.cas.org/express/v8.0-Discover/

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 06:33:05 ON 08 MAR 2006

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 06:33:10 ON 08 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 6 MAR 2006 HIGHEST RN 876011-49-3
DICTIONARY FILE UPDATES: 6 MAR 2006 HIGHEST RN 876011-49-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\QUERIES\10666857.str



chain nodes :
10
ring nodes :
1 2 3 4 5 6 7 8 9
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9

```
exact/norm bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-9  7-8  8-9


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:CLASS



L1      STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1               STR
```




```
Structure attributes must be viewed using STN Express query preparation.


=> s l1
SAMPLE SEARCH INITIATED 06:33:32 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     7211 TO ITERATE

 27.7% PROCESSED     2000 ITERATIONS                                 5 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       139130 TO   149310
PROJECTED ANSWERS:             106 TO      614

L2             5 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 06:33:38 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   143448 TO ITERATE

100.0% PROCESSED   143448 ITERATIONS                             339 ANSWERS
SEARCH TIME: 00.00.03

L3           339 SEA SSS FUL L1

=> s l3 and caplus/lc
      49956922 CAPLUS/LC
L4           332 L3 AND CAPLUS/LC

=> s l3 not l4
L5             7 L3 NOT L4

=> d l5 1-7
```

L5 ANSWER 1 OF 7 REGISTRY COPYRIGHT 2006 ACS on STN
RN 775275-39-3 REGISTRY
ED Entered STN: 05 Nov 2004
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-7-(4,5,6,7-tetrahydro-7-hydroxythieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)
MF C21 H20 N2 O5 S
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 2 OF 7 REGISTRY COPYRIGHT 2006 ACS on STN
RN 601525-63-7 REGISTRY
ED Entered STN: 09 Oct 2003
CN 4H-Quinolizine-3-carboxylic acid, 1-cyclopropyl-9-methyl-4-oxo-8-[4,5,6,7-tetrahydro-7-(methoxymethoxy)thieno[3,2-c]pyridin-2-yl]-, ethyl ester (9CI) (CA INDEX NAME)
MF C25 H28 N2 O5 S
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 3 OF 7 REGISTRY COPYRIGHT 2006 ACS on STN
RN 405143-04-6 REGISTRY
ED Entered STN: 12 Apr 2002
CN 4H-Quinolizine-3-carboxylic acid, 1-cyclopropyl-9-methyl-4-oxo-8-(4,5,6,7-tetrahydro-7-methoxythieno[3,2-c]pyridin-2-yl)-, ethyl ester (9CI) (CA INDEX NAME)
MF C24 H26 N2 O4 S
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 4 OF 7 REGISTRY COPYRIGHT 2006 ACS on STN
RN 405142-97-4 REGISTRY
ED Entered STN: 12 Apr 2002
CN 4H-Quinolizine-3-carboxylic acid, 1-cyclopropyl-9-methyl-4-oxo-8-[4,5,6,7-tetrahydro-6-[(methoxymethoxy)methyl]thieno[3,2-c]pyridin-2-yl]-, ethyl ester (9CI) (CA INDEX NAME)
MF C26 H30 N2 O5 S
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 5 OF 7 REGISTRY COPYRIGHT 2006 ACS on STN
RN 405142-90-7 REGISTRY
ED Entered STN: 12 Apr 2002
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-9-(difluoromethoxy)-4-oxo-
8-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)-, ethyl ester (9CI) (CA
INDEX NAME)
MF C23 H22 F2 N2 O4 S
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 6 OF 7 REGISTRY COPYRIGHT 2006 ACS on STN
RN 405142-78-1 REGISTRY
ED Entered STN: 12 Apr 2002
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-7-fluoro-9-methyl-4-oxo-8-
(4,5,6,7-tetrahydro-6-methylthieno[3,2-c]pyridin-2-yl)-, ethyl ester
(9CI)
(CA INDEX NAME)
MF C24 H25 F N2 O3 S
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 7 OF 7 REGISTRY COPYRIGHT 2006 ACS on STN
RN 405142-72-5 REGISTRY
ED Entered STN: 12 Apr 2002
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-7-fluoro-9-methyl-4-oxo-8-
(4,5,6,7-tetrahydro-4-methylthieno[3,2-c]pyridin-2-yl)-, ethyl ester
(9CI)
(CA INDEX NAME)
MF C24 H25 F N2 O3 S
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

=> fil caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	185.00	185.21

FILE 'CAPLUS' ENTERED AT 06:34:03 ON 08 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 8 Mar 2006 VOL 144 ISS 11
FILE LAST UPDATED: 7 Mar 2006 (20060307/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> d his

L6 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:160840 CAPLUS
DOCUMENT NUMBER: 142:261527
TITLE: Preparation of thienopyridines and furopyridines as protein kinase inhibitors
INVENTOR(S): Betschmann, Patrick; Burchat, Andrew F.; Calderwood, David J.; Curtin, Michael L.; Davidsen, Steven K.; Davis, Heather M.; Frey, Robin R.; Heyman, Howard R.; Hirst, Gavin C.; Hrnciar, Peter; Michaelides, Michael R.; Muckey, Melanie A.; Rafferty, Paul; Wada, Carol K.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 181 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2005043347	A1	20050224	US 2004-899168		20040726
PRIORITY APPLN. INFO.:			US 2003-489734P	P	20030724
			US 2004-567703P	P	20040503

OTHER SOURCE(S): MARPAT 142:261527
GI



I II

AB Title compds. I [wherein X = O, S; Z = C or N; R1 = H, alkenyl, alkoxyalkynyl, aryl, etc.; R2 = absence, H or alkyl; R3 = halo, (un)substituted (hetero)aryl or heterocyclyl, and therapeutically acceptable salts thereof] were prepared as protein kinase inhibitors. For example, urea II was synthesized via Pd-catalyzed coupling reaction of the corresponding 7-iodo-thienopyridine with [3-(dimethylamino)phenyl]boronic acid. Representative compds. I inhibited KDR and Lck at IC50 values of 0.002 μM to 50 μM and 0.03 μM to 50 μM, resp. Therefore, I and their pharmaceutical compns. are useful for the treatment of such as cancer, ocular and cardiovascular diseases.

IT **832694-25-4P 832694-31-2P 832696-16-9P**
832697-53-7P 832697-72-0P 832697-73-1P
832697-74-2P 832697-75-3P 832697-77-5P

L6 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
832697-79-7P 832697-80-0P 845872-14-2P,
4-[4-Amino-3-(2-methyl-1H-indol-5-yl)thieno[3,2-c]pyridin-7-yl]benzonitrile 845872-15-3P, 7-(4-Aminophenyl)-3-(2-methyl-1,3-benzothiazol-5-yl)thieno[3,2-c]pyridin-4-amine 845872-16-4P,
N-[4-[4-Amino-3-(benzo[b]furan-2-yl)thieno[3,2-c]pyridin-7-yl]phenyl]acetamide 845872-18-6P, N-[4-[4-Amino-3-(2,3-dihydro-1H-indol-5-yl)thieno[3,2-c]pyridin-7-yl]phenyl]acetamide
845872-19-7P, N-[4-[4-Amino-3-(2-methyl-1,3-benzothiazol-5-yl)thieno[3,2-c]pyridin-7-yl]phenyl]acetamide 845872-20-0P,
3-(2-Methyl-1H-indol-5-yl)-7-[4-(methylsulfonyl)phenyl]thieno[3,2-c]pyridin-4-amine 845872-21-1P, 7-[4-(Ethylsulfonyl)phenyl]-3-(2-methyl-1H-indol-5-yl)thieno[3,2-c]pyridin-4-amine 845872-22-2P,
N-[4-[4-Amino-3-(benzo[b]furan-2-yl)thieno[3,2-c]pyridin-7-yl]phenyl]methanesulfonamide 845872-24-4P, N-[4-[4-Amino-3-(7-fluoro-1H-indol-5-yl)thieno[3,2-c]pyridin-7-yl]phenyl]methanesulfonamide
845872-26-6P, N-[4-[4-Amino-3-(2-methyl-1,3-benzothiazol-5-yl)thieno[3,2-c]pyridin-7-yl]phenyl]methanesulfonamide
845872-27-7P, N-[4-[4-Amino-3-(1H-indol-5-yl)thieno[3,2-c]pyridin-7-yl]phenyl]methanesulfonamide 845872-28-8P,
N-[4-[4-Amino-3-(2,3-dihydro-1H-indol-5-yl)thieno[3,2-c]pyridin-7-yl]phenyl]methanesulfonamide 845872-29-9P, N-[4-[4-Amino-3-(2-methyl-1,3-benzoxazol-5-yl)thieno[3,2-c]pyridin-7-yl]phenyl]methanesulfonamide 845872-32-4P, N-[4-[4-Amino-3-(2-methyl-1H-indol-5-yl)thieno[3,2-c]pyridin-7-yl]phenyl]methanesulfonamide
845872-33-5P, 3-(2-Methyl-1H-indol-5-yl)-7-[3-(methylsulfonyl)phenyl]thieno[3,2-c]pyridin-4-amine 845872-63-1P
, 3-(2-Methyl-1H-indol-5-yl)-7-phenylthieno[3,2-c]pyridin-4-amine
845872-67-5P, 7-(4-Aminophenyl)-3-(1H-indol-5-yl)thieno[3,2-c]pyridin-4-amine 845872-68-6P, N-[3-[4-Amino-3-(2-methyl-1H-indol-5-yl)thieno[3,2-c]pyridin-7-yl]phenyl]methanesulfonamide
845872-69-7P, N-[4-[4-Amino-3-(2-methyl-1H-indol-5-yl)thieno[3,2-c]pyridin-7-yl]phenyl]acetamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(inhibitor; prepn. of thienopyridines and furopyridines as protein kinase inhibitors)

RN 832694-25-4 CAPLUS
CN 2-Propenamide, 3-[4-amino-3-(1,3-benzodioxol-5-yl)thieno[3,2-c]pyridin-7-yl]-N-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 832694-31-2 CAPLUS

L6 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 2-Propenamide, 3-[4-amino-3-(1H-indol-5-yl)thieno[3,2-c]pyridin-7-yl]-N-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 832696-16-9 CAPLUS
CN Thieno[3,2-c]pyridin-4-amine, 3-(1H-indol-6-yl)- (9CI) (CA INDEX NAME)



RN 832697-53-7 CAPLUS
CN Thieno[3,2-c]pyridin-4-amine, 3-(1H-indol-5-yl)- (9CI) (CA INDEX NAME)



RN 832697-72-0 CAPLUS
CN 2-Propenamide, 3-[4-amino-3-(1H-indol-6-yl)thieno[3,2-c]pyridin-7-yl]-N-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L6 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 832697-73-1 CAPLUS
CN 2-Propenamide, 3-[4-amino-3-(1-methyl-1H-indol-6-yl)thieno[3,2-c]pyridin-7-yl]-N-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 832697-74-2 CAPLUS
CN 2-Propenamide, 3-[4-amino-3-(2-methyl-1H-indol-5-yl)thieno[3,2-c]pyridin-7-yl]-N-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 832697-75-3 CAPLUS
CN Piperazinone, 4-[[4-amino-3-(1H-indol-5-yl)thieno[3,2-c]pyridin-7-yl]methyl]- (9CI) (CA INDEX NAME)



RN 832697-77-5 CAPLUS
CN 2-Propenamide,
3-[4-amino-3-(1H-indol-5-yl)thieno[3,2-c]pyridin-7-yl]-N-(4-pyridinylmethyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 832697-79-7 CAPLUS
CN 2-Propenamide,
3-[4-amino-3-(1H-indol-5-yl)thieno[3,2-c]pyridin-7-yl]-N-[3-(1H-imidazol-1-yl)propyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 832697-80-0 CAPLUS
CN 2-Propenamide,
3-[4-amino-3-(1H-indol-5-yl)thieno[3,2-c]pyridin-7-yl]-N-[2-(diethylamino)ethyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 845872-14-2 CAPLUS
CN Benzonitrile,
4-[4-amino-3-(2-methyl-1H-indol-5-yl)thieno[3,2-c]pyridin-7-yl]- (9CI) (CA INDEX NAME)



RN 845872-15-3 CAPLUS
CN Thieno[3,2-c]pyridin-4-amine, 7-(4-aminophenyl)-3-(2-methyl-5-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 845872-16-4 CAPLUS
CN Acetamide, N-[4-[4-amino-3-(2-benzofuranyl)thieno[3,2-c]pyridin-7-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 845872-18-6 CAPLUS
CN Acetamide,
N-[4-[4-amino-3-(2,3-dihydro-1H-indol-5-yl)thieno[3,2-c]pyridin-7-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 845872-19-7 CAPLUS
CN Acetamide,
N-[4-[4-amino-3-(2-methyl-5-benzothiazolyl)thieno[3,2-c]pyridin-7-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 845872-20-0 CAPLUS
CN Thieno[3,2-c]pyridin-4-amine, 3-(2-methyl-1H-indol-5-yl)-7-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 845872-21-1 CAPLUS
CN Thieno[3,2-c]pyridin-4-amine, 7-[4-(ethylsulfonyl)phenyl]-3-(2-methyl-1H-indol-5-yl)- (9CI) (CA INDEX NAME)



RN 845872-22-2 CAPLUS
CN Methanesulfonamide, N-[4-[4-amino-3-(2-benzofuranyl)thieno[3,2-c]pyridin-7-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 845872-24-4 CAPLUS



RN 845872-28-8 CAPLUS
CN Methanesulfonamide, N-[4-[4-amino-3-(2,3-dihydro-1H-indol-5-yl)thieno[3,2-c]pyridin-7-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 845872-29-9 CAPLUS
CN Methanesulfonamide, N-[4-[4-amino-3-(2-methyl-5-benzoxazolyl)thieno[3,2-c]pyridin-7-yl]phenyl]- (9CI) (CA INDEX NAME)



CN Methanesulfonamide, N-[4-[4-amino-3-(7-fluoro-1H-indol-5-yl)thieno[3,2-c]pyridin-7-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 845872-26-6 CAPLUS
CN Methanesulfonamide, N-[4-[4-amino-3-(2-methyl-5-benzothiazolyl)thieno[3,2-c]pyridin-7-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 845872-27-7 CAPLUS
CN Methanesulfonamide, N-[4-[4-amino-3-(1H-indol-5-yl)thieno[3,2-c]pyridin-7-yl]phenyl]- (9CI) (CA INDEX NAME)

RN 845872-32-4 CAPLUS
CN Methanesulfonamide, N-[4-[4-amino-3-(2-methyl-1H-indol-5-yl)thieno[3,2-c]pyridin-7-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 845872-33-5 CAPLUS
CN Thieno[3,2-c]pyridin-4-amine, 3-(2-methyl-1H-indol-5-yl)-7-[3-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 845872-63-1 CAPLUS
CN Thieno[3,2-c]pyridin-4-amine, 3-(2-methyl-1H-indol-5-yl)-7-phenyl- (9CI) (CA INDEX NAME)



RN 845872-67-5 CAPLUS
CN Thieno[3,2-c]pyridin-4-amine, 7-(4-aminophenyl)-3-(1H-indol-5-yl)- (9CI) (CA INDEX NAME)



RN 845872-68-6 CAPLUS
CN Methanesulfonamide, N-[3-[4-amino-3-(2-methyl-1H-indol-5-yl)thieno[3,2-c]pyridin-7-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 845872-69-7 CAPLUS
CN Acetamide, N-[4-[4-amino-3-(2-methyl-1H-indol-5-yl)thieno[3,2-c]pyridin-7-yl]phenyl]- (9CI) (CA INDEX NAME)



IT 837391-40-9P 837391-41-0P 837391-56-7P
837391-58-9P 837391-62-5P 837391-63-6P
837391-67-0P 837391-68-1P 837391-69-2P
837391-72-7P 837391-73-8P 837391-75-0P
837391-76-1P 837391-77-2P 837391-78-3P

CN 2-Propenamide, 3-[4-amino-3-(7-fluoro-1H-indol-5-yl)thieno[3,2-c]pyridin-7-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 837391-62-5 CAPLUS
CN 2-Propenamide, 3-[4-amino-3-(7-fluoro-2-methyl-1H-indol-5-yl)thieno[3,2-c]pyridin-7-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 837391-63-6 CAPLUS
CN 2-Propenamide, 3-[4-amino-3-(2-methyl-1H-indol-5-yl)thieno[3,2-c]pyridin-7-yl]-N-[3-(1H-imidazol-1-yl)propyl]- (9CI) (CA INDEX NAME)

837391-79-4P 837391-80-7P 837391-81-8P
837391-82-9P 837391-83-0P 837391-95-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of thienopyridines and furopyridines as protein kinase inhibitors)

RN 837391-40-9 CAPLUS
CN Thieno[3,2-c]pyridine-7-propanamide, 4-amino-3-(1H-indol-6-yl)-N-methyl- (9CI) (CA INDEX NAME)



RN 837391-41-0 CAPLUS
CN Thieno[3,2-c]pyridine-7-propanamide, 4-amino-3-(1H-indol-5-yl)-N-methyl- (9CI) (CA INDEX NAME)



RN 837391-56-7 CAPLUS
CN 2-Propenamide, 3-[4-amino-3-(2-methyl-1H-indol-5-yl)thieno[3,2-c]pyridin-7-yl]-N-[2-(diethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 837391-58-9 CAPLUS



RN 837391-67-0 CAPLUS
CN 2-Propenamide, 3-(4-amino-3-benzo[b]thien-5-ylthieno[3,2-c]pyridin-7-yl)-N-methyl- (9CI) (CA INDEX NAME)



RN 837391-68-1 CAPLUS
CN 2-Propenamide, 3-[4-amino-3-[2-(trifluoromethyl)-1H-indol-5-yl]thieno[3,2-c]pyridin-7-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 837391-69-2 CAPLUS
CN 2-Propenamide, 3-[4-amino-3-(2-methyl-1H-indol-5-yl)thieno[3,2-c]pyridin-7-yl]-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 837391-72-7 CAPLUS
CN 2-Propenamide, 3-[4-amino-3-(2-methyl-5-benzothiazolyl)thieno[3,2-c]pyridin-7-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 837391-73-8 CAPLUS
CN 2-Propenamide, 3-[4-amino-3-(2,3-dihydro-2-oxo-1H-indol-5-yl)thieno[3,2-c]pyridin-7-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 837391-75-0 CAPLUS
CN 2-Propenamide, 3-[4-amino-3-(2-benzofuranyl)thieno[3,2-c]pyridin-7-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 837391-76-1 CAPLUS
CN 2-Propenamide, 3-[4-amino-3-(5-benzofuranyl)thieno[3,2-c]pyridin-7-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 837391-77-2 CAPLUS
CN 2-Propenamide, 3-[4-amino-3-(6-quinolinyl)thieno[3,2-c]pyridin-7-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 837391-78-3 CAPLUS
CN 2-Propenamide, 3-[4-amino-3-(1,2-benzisoxazol-5-yl)thieno[3,2-c]pyridin-7-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 837391-79-4 CAPLUS
CN 2-Propenamide, 3-[4-amino-3-(2,3-dihydro-1H-indol-5-yl)thieno[3,2-c]pyridin-7-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 837391-80-7 CAPLUS
CN 2-Propenamide, 3-[4-amino-3-(2-methyl-6-benzothiazolyl)thieno[3,2-c]pyridin-7-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 837391-81-8 CAPLUS
CN Thieno[3,2-c]pyridin-4-amine, 3-(2-methyl-1H-indol-5-yl)-7-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 837391-82-9 CAPLUS
CN Thieno[3,2-c]pyridin-4-amine, 7-(4-aminophenyl)-3-(2-methyl-1H-indol-5-yl)- (9CI) (CA INDEX NAME)



RN 837391-83-0 CAPLUS
CN Acetamide, N-[3-[4-amino-3-(2-methyl-1H-indol-5-yl)thieno[3,2-c]pyridin-7-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 837391-95-4 CAPLUS
CN Thieno[3,2-c]pyridin-4-amine, 3,7-di-1H-indol-6-yl- (9CI) (CA INDEX NAME)



IT **837392-68-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of thienopyridines and furopyridines as protein kinase inhibitors)
RN 837392-68-4 CAPLUS
CN 1H-Indole-1-carboxylic acid, 5-[4-amino-7-[3-(methylamino)-3-oxo-1-propenyl]thieno[3,2-c]pyridin-3-yl]-2,3-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



ACCESSION NUMBER: 2005:99165 CAPLUS
DOCUMENT NUMBER: 142:198046
TITLE: Preparation of thienopyridines as protein kinase inhibitors
INVENTOR(S): Betschmann, Patrick; Burchat, Andrew F.; Calderwood, David J.; Curtin, Michael L.; Davidsen, Steven K.; Davis, Heather M.; Frey, Robin R.; Heyman, Howard R.; Hirst, Gavin C.; Hrnciar, Peter; Michaelides, Michael R.; Muckey, Melanie A.; Rafferty, Paul; Wada, Carol K.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 106 pp., Cont.-in-part of U.S. Ser. No. 626,092.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005026944	A1	20050203	US 2004-838132	20040503
US 2005020619	A1	20050127	US 2003-626092	20030724
WO 2005010009	A1	20050203	WO 2004-US24003	20040726

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-626092 A2 20030724
US 2004-838132 A 20040503

OTHER SOURCE(S): MARPAT 142:198046
GI



I



II

AB Title compds. I [wherein X = O, S; R1 = H, alkenyl, alkoxyalkynyl, aryl,

etc.; R2 = H or alkyl; R3 = halo, (un)substituted (hetero)aryl or heterocyclyl, or therapeutically acceptable salts thereof] were prepd. as protein kinase inhibitors. For example, urea II was synthesized via addn.
reaction of the corresponding amine (prepn. given) with 1-isocyanato-3-methylbenzene. Representative compds. I inhibited KDR and Lck at IC50 values of 0.002 μM to 50 μM and 0.06 μM to 50 μM, resp. Therefore, I and their pharmaceutical compns. are useful for the treatment of such as cancer, ocular and cardiovascular diseases.

IT **832694-25-4P 832694-31-2P 832696-16-9P**
832697-53-7P 832697-72-0P 832697-73-1P
832697-74-2P 832697-75-3P 832697-77-5P
832697-79-7P 832697-80-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(kinase inhibitor; preparation of thienopyridines as protein kinase inhibitors)
RN 832694-25-4 CAPLUS
CN 2-Propenamide, 3-[4-amino-3-(1,3-benzodioxol-5-yl)thieno[3,2-c]pyridin-7-yl]-N-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 832694-31-2 CAPLUS
CN 2-Propenamide, 3-[4-amino-3-(1H-indol-5-yl)thieno[3,2-c]pyridin-7-yl]-N-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 832696-16-9 CAPLUS
CN Thieno[3,2-c]pyridin-4-amine, 3-(1H-indol-6-yl)- (9CI) (CA INDEX NAME)



RN 832697-53-7 CAPLUS
CN Thieno[3,2-c]pyridin-4-amine, 3-(1H-indol-5-yl)- (9CI) (CA INDEX NAME)



RN 832697-72-0 CAPLUS
CN 2-Propenamide, 3-[4-amino-3-(1H-indol-6-yl)thieno[3,2-c]pyridin-7-yl]-N-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 832697-73-1 CAPLUS
CN 2-Propenamide, 3-[4-amino-3-(1-methyl-1H-indol-6-yl)thieno[3,2-c]pyridin-7-yl]-N-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 832697-74-2 CAPLUS
CN 2-Propenamide, 3-[4-amino-3-(2-methyl-1H-indol-5-yl)thieno[3,2-c]pyridin-7-yl]-N-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 832697-75-3 CAPLUS
CN Piperazinone, 4-[[4-amino-3-(1H-indol-5-yl)thieno[3,2-c]pyridin-7-yl]methyl]- (9CI) (CA INDEX NAME)



RN 832697-77-5 CAPLUS
CN 2-Propenamide, 3-[4-amino-3-(1H-indol-5-yl)thieno[3,2-c]pyridin-7-yl]-N-(4-pyridinylmethyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 832697-79-7 CAPLUS
CN 2-Propenamide, 3-[4-amino-3-(1H-indol-5-yl)thieno[3,2-c]pyridin-7-yl]-N-[3-(1H-imidazol-1-yl)propyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 832697-80-0 CAPLUS
CN 2-Propenamide, 3-[4-amino-3-(1H-indol-5-yl)thieno[3,2-c]pyridin-7-yl]-N-(2-(diethylamino)ethyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 837391-40-9P 837391-41-0P 837391-56-7P
837391-58-9P 837391-62-5P 837391-63-6P
837391-67-0P 837391-68-1P 837391-69-2P
837391-72-7P 837391-73-8P 837391-75-0P
837391-76-1P 837391-77-2P 837391-78-3P
837391-79-4P 837391-80-7P 837391-81-8P
837391-82-9P 837391-83-0P 837391-95-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thienopyridines as protein kinase inhibitors)

RN 837391-40-9 CAPLUS
CN Thieno[3,2-c]pyridine-7-propanamide, 4-amino-3-(1H-indol-6-yl)-N-methyl- (9CI) (CA INDEX NAME)



RN 837391-41-0 CAPLUS
CN Thieno[3,2-c]pyridine-7-propanamide, 4-amino-3-(1H-indol-5-yl)-N-methyl- (9CI) (CA INDEX NAME)



RN 837391-63-6 CAPLUS
CN 2-Propenamide,
3-[4-amino-3-(2-methyl-1H-indol-5-yl)thieno[3,2-c]pyridin-7-yl]-N-[3-(1H-imidazol-1-yl)propyl]- (9CI) (CA INDEX NAME)



RN 837391-67-0 CAPLUS
CN 2-Propenamide,
3-(4-amino-3-benzo[b]thien-5-ylthieno[3,2-c]pyridin-7-yl)-N-methyl- (9CI) (CA INDEX NAME)





RN 837391-56-7 CAPLUS
CN 2-Propenamide,
3-[4-amino-3-(2-methyl-1H-indol-5-yl)thieno[3,2-c]pyridin-7-yl]-N-[2-(diethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 837391-58-9 CAPLUS
CN 2-Propenamide,
3-[4-amino-3-(7-fluoro-1H-indol-5-yl)thieno[3,2-c]pyridin-7-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 837391-62-5 CAPLUS
CN 2-Propenamide, 3-[4-amino-3-(7-fluoro-2-methyl-1H-indol-5-yl)thieno[3,2-c]pyridin-7-yl]-N-methyl- (9CI) (CA INDEX NAME)

RN 837391-68-1 CAPLUS
CN 2-Propenamide,
3-[4-amino-3-[2-(trifluoromethyl)-1H-indol-5-yl]thieno[3,2-c]pyridin-7-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 837391-69-2 CAPLUS
CN 2-Propenamide,
3-[4-amino-3-(2-methyl-1H-indol-5-yl)thieno[3,2-c]pyridin-7-yl]-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 837391-72-7 CAPLUS
CN 2-Propenamide, 3-[4-amino-3-(2-methyl-5-benzothiazolyl)thieno[3,2-c]pyridin-7-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 837391-73-8 CAPLUS
CN 2-Propenamide, 3-[4-amino-3-(2,3-dihydro-2-oxo-1H-indol-5-yl)thieno[3,2-c]pyridin-7-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 837391-75-0 CAPLUS
CN 2-Propenamide, 3-[4-amino-3-(2-benzofuranyl)thieno[3,2-c]pyridin-7-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 837391-76-1 CAPLUS
CN 2-Propenamide, 3-[4-amino-3-(5-benzofuranyl)thieno[3,2-c]pyridin-7-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 837391-77-2 CAPLUS
CN 2-Propenamide, 3-[4-amino-3-(6-quinolinyl)thieno[3,2-c]pyridin-7-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 837391-78-3 CAPLUS
CN 2-Propenamide, 3-[4-amino-3-(1,2-benzisoxazol-5-yl)thieno[3,2-c]pyridin-7-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 837391-79-4 CAPLUS
CN 2-Propenamide, 3-[4-amino-3-(2,3-dihydro-1H-indol-5-yl)thieno[3,2-c]pyridin-7-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 837391-80-7 CAPLUS
CN 2-Propenamide, 3-[4-amino-3-(2-methyl-6-benzothiazolyl)thieno[3,2-c]pyridin-7-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 837391-81-8 CAPLUS
CN Thieno[3,2-c]pyridin-4-amine, 3-(2-methyl-1H-indol-5-yl)-7-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 837391-82-9 CAPLUS
CN Thieno[3,2-c]pyridin-4-amine, 7-(4-aminophenyl)-3-(2-methyl-1H-indol-5-yl)- (9CI) (CA INDEX NAME)



RN 837391-83-0 CAPLUS
CN Acetamide, N-[3-[4-amino-3-(2-methyl-1H-indol-5-yl)thieno[3,2-c]pyridin-7-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 837391-95-4 CAPLUS
CN Thieno[3,2-c]pyridin-4-amine, 3,7-di-1H-indol-6-yl- (9CI) (CA INDEX NAME)



IT 837392-68-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of thienopyridines as protein kinase inhibitors)
RN 837392-68-4 CAPLUS
CN 1H-Indole-1-carboxylic acid, 5-[4-amino-7-[3-(methylamino)-3-oxo-1-

L6 ANSWER 2 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
propenyl]thieno[3,2-c]pyridin-3-yl]-2,3-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L6 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:78240 CAPLUS
DOCUMENT NUMBER: 142:176820
TITLE: Preparation of thienopyridines as protein kinase inhibitors
INVENTOR(S): Betschmann, Patrick; Burchat, Andrew; Calderwood, David; Curtin, Michael L.; Davidsen, Steven K.; Davis, Heather M.; Frey, Robin R.; Heyman, Howard R.; Hirst, Gavin; Hrnciar, Peter; Michaelides, Michael; Rafferty, Paul
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 76 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005020619	A1	20050127	US 2003-626092	20030724
US 2005026944	A1	20050203	US 2004-838132	20040503
WO 2005010009	A1	20050203	WO 2004-US24003	20040726

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-626092 A2 20030724
US 2004-838132 A 20040503

OTHER SOURCE(S): MARPAT 142:176820
GI



AB Title compds. I [wherein R1 = H, nitro, (un)substituted alk(en/yn)yl or

L6 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
amino; R2 = H or alkyl; R3 = halo, (un)substituted (hetero)aryl or heterocyclyl, or therapeutically acceptable salts thereof] were prepd. as protein kinase inhibitors. For example, urea II was synthesized via addn.
reaction of the corresponding amine (prepn. given) with 1-isocyanato-3-methylbenzene. Exemplified compds. I inhibited KDR and Lck
with IC50 values of from 0.004 FM to 50 μM and from 0.06 μM to 50 μM, resp. Therefore, I and their pharmaceutical compns. are useful for the treatment of such as cancer, ocular and cardiovascular diseases.

IT **832694-25-4P 832694-31-2P 832696-16-9P**
832697-53-7P 832697-72-0P 832697-73-1P
832697-74-2P 832697-75-3P 832697-77-5P
832697-79-7P 832697-80-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(kinase inhibitor; preparation of thienopyridines as protein kinase inhibitors)

RN 832694-25-4 CAPLUS
CN 2-Propenamide, 3-[4-amino-3-(1,3-benzodioxol-5-yl)thieno[3,2-c]pyridin-7-yl]-N-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 832694-31-2 CAPLUS
CN 2-Propenamide, 3-[4-amino-3-(1H-indol-5-yl)thieno[3,2-c]pyridin-7-yl]-N-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L6 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 832696-16-9 CAPLUS
CN Thieno[3,2-c]pyridin-4-amine, 3-(1H-indol-6-yl)- (9CI) (CA INDEX NAME)



RN 832697-53-7 CAPLUS
CN Thieno[3,2-c]pyridin-4-amine, 3-(1H-indol-5-yl)- (9CI) (CA INDEX NAME)



RN 832697-72-0 CAPLUS
CN 2-Propenamide, 3-[4-amino-3-(1H-indol-6-yl)thieno[3,2-c]pyridin-7-yl]-N-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 832697-73-1 CAPLUS
CN 2-Propenamide,
3-[4-amino-3-(1-methyl-1H-indol-6-yl)thieno[3,2-c]pyridin-7-yl]-N-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 832697-74-2 CAPLUS
CN 2-Propenamide,
3-[4-amino-3-(2-methyl-1H-indol-5-yl)thieno[3,2-c]pyridin-7-yl]-N-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 832697-75-3 CAPLUS
CN Piperazinone, 4-[[4-amino-3-(1H-indol-5-yl)thieno[3,2-c]pyridin-7-yl]methyl]- (9CI) (CA INDEX NAME)



RN 832697-77-5 CAPLUS
CN 2-Propenamide,
3-[4-amino-3-(1H-indol-5-yl)thieno[3,2-c]pyridin-7-yl]-N-(4-pyridinylmethyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 832697-79-7 CAPLUS
CN 2-Propenamide,
3-[4-amino-3-(1H-indol-5-yl)thieno[3,2-c]pyridin-7-yl]-N-[3-(1H-imidazol-1-yl)propyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 832697-80-0 CAPLUS
CN 2-Propenamide,
3-[4-amino-3-(1H-indol-5-yl)thieno[3,2-c]pyridin-7-yl]-N-[2-(diethylamino)ethyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L6 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:1015877 CAPLUS
DOCUMENT NUMBER: 142:6506
TITLE: Preparation of furopyridines and thienopyridines for inhibiting tyrosine kinases
INVENTOR(S): Miyazaki, Yasushi
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004100947	A2	20041125	WO 2004-US13668	20040429
WO 2004100947	A3	20050324		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1620094	A2	20060201	EP 2004-760864	20040429
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				

PRIORITY APPLN. INFO.: US 2003-468175P P 20030506
WO 2004-US13668 W 20040429

OTHER SOURCE(S): MARPAT 142:6506
GI

L6 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I II

AB The title compds. I [Y = S, O; R1 = (un)substituted Ph, methylenedioxyphenyl, naphthyl, etc.; R2 = H, halo, pyridyl, (un)substituted Ph], useful for treating and preventing tumors and cancers, and methods for treating proliferative diseases associated with the imbalance or inappropriate activity of tyrosine kinases implicated in proliferative diseases, are disclosed. E.g., a multi-step synthesis of II, starting from 2-furfural, was given. The compds. I were tested against EphB4, Tie-2, VEGFR-2 and Src kinases (biol. data given for representative compds. I). The pharmaceutical composition comprising the compound I is claimed.

IT **799293-64-4P 799293-69-9P 799293-71-3P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of furopyridines and thienopyridines for inhibiting tyrosine kinases)

RN 799293-64-4 CAPLUS
CN Thieno[3,2-c]pyridin-4-amine, 3-(1,3-benzodioxol-5-yl)-7-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 799293-69-9 CAPLUS
CN Thieno[3,2-c]pyridin-4-amine, 3-(1H-indol-5-yl)-7-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 799293-71-3 CAPLUS
CN Thieno[3,2-c]pyridin-4-amine, 3-(2-methyl-5-benzothiazolyl)-7-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



L6 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:878380 CAPLUS
DOCUMENT NUMBER: 141:379931
TITLE: Preparation of aminopyrimidines as IKK inhibitors for treating autoimmune diseases and inflammations
INVENTOR(S): Bollbuck, Birgit; Denholm, Alastair; Eder, Joerg; Herspergerr, Rene; Janser, Philipp; Revesz, Laszlo; Schlapbach, Achim; Waelchli, Rudolf
PATENT ASSIGNEE(S): Novartis Ag, Switz.; Novartis Pharma G.m.b.H.
SOURCE: PCT Int. Appl., 217 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004089913	A1	20041021	WO 2004-EP3819	20040408
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2521340	AA	20041021	CA 2004-2521340	20040408
EP 1615898	A1	20060118	EP 2004-726485	20040408
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				

PRIORITY APPLN. INFO.: GB 2003-8466 A 20030411
WO 2004-EP3819 W 20040408

OTHER SOURCE(S): MARPAT 141:379931
GI

L6 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I



II

AB Title compds. I [wherein R1 = H, (un)substituted lower alkyl, aryl, heterocycloalkyl, etc.; R2 = (un)substituted aryl, wherein aryl is not 4-(4-fluorophenyl)-1(1-methylpiperdin-4-yl)imidazole; each R3, R4 = independently H, CN, halo, OH, lower alkoxy, (un)substituted lower alkyl; X = CR6R7; Y = CR8R9; Z = CR10R11; W = CR12R13; each R6 to R13 = independently H, (un)substituted lower alkyl, lower alkoxy, CH2O-NH2, etc.; wherein at least one of R6 to R13 is not equal to H; any pair of R6 to R13 are joined together to form an (un)substituted C1 to C4 bridge in which one or more of the bridge atoms is optionally replaced by O, S, NH and derivs.; their pharmaceutically acceptable salts, esters or prodrugs] were prepared as inhibitors of IKK protein kinase (IKK) and production of tumor necrosis factor-α (TNF-α). For e.g., a 3-step synthesis of II was given. I showed IC50 values range of 20 to 1,000 nM in the IκB kinase activity assay. I, at 30 mg/kg p.o., i.v. or s.c., inhibited TNF-α production to the extent of up to about 50% or more in LPS stimulated mice. I are useful as immunosuppressants and antiinflammatory agents.

IT **778644-75-0P**, (2,2,6,6-Tetramethylpiperidin-4-yl)[4-(thieno[3,2-c]pyridin-2-yl)pyrimidin-2-yl]amine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(IKK inhibitor; preparation of aminopyrimidines as inhibitors of TNF-α production for treating autoimmune diseases and inflammations)

RN 778644-75-0 CAPLUS

CN 2-Pyrimidinamine, N-(2,2,6,6-tetramethyl-4-piperidinyl)-4-thieno[3,2-c]pyridin-2-yl- (9CI) (CA INDEX NAME)

L6 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:414631 CAPLUS
DOCUMENT NUMBER: 140:423660
TITLE: Preparation of thieno[3,2-c]pyridines and related compounds as antiinflammatory agents
INVENTOR(S): Burkitt, Simon A.; Cardozo, Mario G.; Cushing, Timothy D.; DeGraffenreid, Michael R.; Farthing, Christopher N.; Hao, Xiaolin; Jaen, Juan C.; Jiao, Xian Yun; Kopecky, David J.; Labelle, Marc; Lively, Sarah E.; McMinn, Dustin L.; Rasmussen, Sven P.; Shin, Youngsook; Smith, Andrew; Smith, Marie-Louise
PATENT ASSIGNEE(S): Tularik Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 70 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004097485	A1	20040520	US 2003-666857	20030919
CA 2502429	AA	20040521	CA 2003-2502429	20030919
WO 2004041285	A1	20040521	WO 2003-US29143	20030919
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003270701	A1	20040607	AU 2003-270701	20030919
EP 1556053	A1	20050727	EP 2003-752410	20030919
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.: US 2002-422531P P 20021031
WO 2003-US29143 W 20030919

OTHER SOURCE(S): MARPAT 140:423660
GI



II

L6 ANSWER 6 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

AB The invention relates to title fused heterobicyclic compds. QLWR1R2 (I) [wherein W = 5-6, 6-6, or 5-5 fused bicyclic ring system wherein one or both rings are aromatic, containing N and 0-3 addnl. N, O, or S; R1 = carbamoyl, acyl, hydroxyiminomethyl, acylamino, sulfamoyl, heteroaryl, etc.; R2 = (un)substituted amino, heterocyclyl, OH; L = bond, alkylene, CO, CONR3, SO2NR3, CR3=CR4, O, S, NR3; R3 and R4 = independently H, (cyclo)alkyl, (hetero)aryl(alkyl), heterocyclyl; Q = cycloalkyl, (cyclo)alkenyl, alkynyl, alkoxy, halo, (hetero)aryl, heterocyclyl; with provisos; and pharmaceutically acceptable salts, hydrates, solvates, or prodrugs thereof], which were prepared as inhibitors of IKKα and IKKβ enzymes, mediators of TNF-α and IL-1 induced IκB phosphorylation and degradation For example, reaction of 2-bromo-7-cyano-4-(p-methoxybenzylamino)thieno[3,2-c]pyridine with concentrated H2SO4 gave 2-bromo-7-carboxamido-4-aminothieno[3,2-c]pyridine•H2SO4, which was coupled with 3,4,5-trimethoxybenzeneboronic acid in the presence of K2CO3 and PdCl2(dppf):DCM complex in DMF and H2O to afford II. All exemplified compds. inhibited recombinant, full-length IKKβ enzyme with IC50 values of ≤10 μM, and selected compds. displayed IC50 values ≤10 μM against recombinant, full-length IRAK-1 and IRAK-4 enzymes. Thus, I and their pharmaceutical compns. are useful in the treatment of inflammatory, immunoregulatory, metabolic, infectious, and cell proliferative diseases or conditions (no data).

IT **690635-47-3P**, 4-Amino-2-(4-methylthiophen-2-yl)thieno[3,2-c]pyridine-7-carboxylic acid amide **690635-60-0P**, 4-Amino-2-(imidazol-1-yl)thieno[3,2-c]pyridine-7-carboxylic acid amide **690635-62-2P**, 4-Amino-2-(pyrrolidin-1-yl)thieno[3,2-c]pyridine-7-carboxylic acid amide **690635-75-7P**, 4-Amino-2(1H-pyrazol-4-yl)thieno[3,2-c]pyridine-7-carboxylic acid amide **690635-77-9P**, 4-Amino-2-[4-(2-cyanoethyl)-5-methylthien-2-yl]thieno[3,2-c]pyridine-7-carboxylic acid amide **690635-81-5P**, 4-Amino-2-[2-(morpholin-4-ylmethyl)thien-4-yl]thieno[3,2-c]pyridine-7-carboxylic acid amide **690635-82-6P**, 4-Amino-2-(2,2-dioxo-2,3,3a,7a-tetrahydro-1H-benzo[c]thiophen-5-yl)thieno[3,2-c]pyridine-7-carboxylic acid amide **690635-87-1P**, 4-Amino-2-[5-(2-cyanoethyl)thiophen-3-yl]thieno[3,2-c]pyridine-7-carboxylic acid amide **690635-89-3P**, 4-Amino-2-[4-(2-cyanoethyl)-5-(3-hydroxypropyl)thiophen-2-yl]thieno[3,2-c]pyridine-7-carboxylic acid amide **690635-96-2P**, 4-Amino-2-[5-(3-cyanotetrahydrofuran-2-yl)thiophen-3-yl]thieno[3,2-c]pyridine-7-carboxylic acid amide **690636-00-1P**, 4-Amino-2-(2-methoxythiophen-3-yl)thieno[3,2-c]pyridine-7-carboxylic acid amide **690636-01-2P**, 4-Amino-2-(1-methyl-2,2-dioxo-2,3-dihydro-1H-benzo[c]isothiazol-5-yl)thieno[3,2-c]pyridine-7-carboxylic acid amide **690636-43-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(IKK inhibitor; preparation of thieno[3,2-c]pyridines and related fused heterobicyclic compds. as antiinflammatory agents)

RN 690635-47-3 CAPLUS

CN Thieno[3,2-c]pyridine-7-carboxamide, 4-amino-2-(4-methyl-2-thienyl)- (9CI) (CA INDEX NAME)



RN 690635-60-0 CAPLUS
CN Thieno[3,2-c]pyridine-7-carboxamide, 4-amino-2-(1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)



RN 690635-62-2 CAPLUS
CN Thieno[3,2-c]pyridine-7-carboxamide, 4-amino-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 690635-75-7 CAPLUS
CN Thieno[3,2-c]pyridine-7-carboxamide, 4-amino-2-(1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)



RN 690635-77-9 CAPLUS
CN Thieno[3,2-c]pyridine-7-carboxamide, 4-amino-2-[4-(2-cyanoethyl)-5-methyl-2-thienyl]- (9CI) (CA INDEX NAME)



RN 690635-81-5 CAPLUS
CN Thieno[3,2-c]pyridine-7-carboxamide, 4-amino-2-[5-(4-morpholinylmethyl)-3-thienyl]- (9CI) (CA INDEX NAME)



RN 690635-82-6 CAPLUS
CN Thieno[3,2-c]pyridine-7-carboxamide, 4-amino-2-(1,3,3a,7a-tetrahydro-2,2-dioxidobenzo[c]thien-5-yl)- (9CI) (CA INDEX NAME)



RN 690635-87-1 CAPLUS
CN Thieno[3,2-c]pyridine-7-carboxamide, 4-amino-2-[5-(2-cyanoethyl)-3-thienyl]- (9CI) (CA INDEX NAME)



RN 690635-89-3 CAPLUS
CN Thieno[3,2-c]pyridine-7-carboxamide, 4-amino-2-[4-(2-cyanoethyl)-5-(3-hydroxypropyl)-2-thienyl]- (9CI) (CA INDEX NAME)



RN 690635-96-2 CAPLUS
CN Thieno[3,2-c]pyridine-7-carboxamide, 4-amino-2-[5-(3-cyanotetrahydro-2-furanyl)-3-thienyl]- (9CI) (CA INDEX NAME)



RN 690636-00-1 CAPLUS
CN Thieno[3,2-c]pyridine-7-carboxamide, 4-amino-2-(2-methoxy-3-thienyl)- (9CI) (CA INDEX NAME)



RN 690636-01-2 CAPLUS
CN Thieno[3,2-c]pyridine-7-carboxamide, 4-amino-2-(1,3-dihydro-1-methyl-2,2-dioxido-2,1-benzisothiazol-5-yl)- (9CI) (CA INDEX NAME)



RN 690636-43-2 CAPLUS
CN Thieno[3,2-c]pyridine-7-carboxamide, 4-amino-2-(4-thiazolyl)- (9CI) (CA INDEX NAME)



IT **690635-61-1P**, 2-(Imidazol-1-yl)-4-(4-methoxybenzylamino)thieno[3,2-c]pyridine-7-carbonitrile **690635-76-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of thieno[3,2-c]pyridines and related fused heterobicyclic compds. as antiinflammatory agents)

RN 690635-61-1 CAPLUS
CN Thieno[3,2-c]pyridine-7-carbonitrile, 2-(1H-imidazol-1-yl)-4-[[(4-methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 690635-76-8 CAPLUS
CN Thieno[3,2-c]pyridine-7-carboxamide, 4-amino-2-[1-(triphenylmethyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



ACCESSION NUMBER: 2003:734778 CAPLUS
DOCUMENT NUMBER: 139:261168
TITLE: Preparation of 4-oxo-4H-quinolizine-3-carboxylic acid derivatives as antibacterial agents
INVENTOR(S): Oya, Satoshi; Masuda, Nobuhisa; Kuroki, Yoshiaki; Inoue, Teruhiko; Okudo, Makoto; Iwata, Toshihide; Kokubo, Koji; Mizuno, Hajime; Hagiwara, Masahiko
PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan; Ube Industries, Ltd.
SOURCE: Jpn. Kokai Tokkyo Koho, 146 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003261566	A2	20030919	JP 2002-65126	20020311
PRIORITY APPLN. INFO.:			JP 2002-65126	20020311

OTHER SOURCE(S): MARPAT 139:261168
GI



I





AB Claimed are drugs containing 4-oxo-4H-quinolizine-3-carboxylic acid derivs.
[I; R1 = H, C1-6 alkyl optionally substituted by 1 or ≥2 halo, C3-7 cycloalkyl optionally substituted by 1 or ≥2 C1-6 alkyl or halo, aryl or heteroaryl each optionally substituted by 1 or ≥2 halo or NH2; R2 = H, halo, cyano, HO, C1-6 alkyl or C1-6 alkoxy optionally substituted by 1 or ≥2 halo; R3 = H, halo; R4 = H, halo, NO2, NH2, C1-6 alkyl; R5 = Q, Q1; wherein the ring A = heteroaryl ring; the ring G = C5-8 cycloalkene or cycloalkane optionally having the ring carbon atom arbitrarily replaced by N, O, or S atom; R6a, R6c = H, halo, HO, NO2, NH2, cyano, C1-4 alkyl or C1-4 alkoxy optionally substituted by 1 or ≥2 halo; R7a, R7d = H, halo, HO, NO2, cyano, C1-4 alkyl or C1-4 alkoxy optionally substituted by 1 or ≥2 halo, hydroxy-C1-4 alkyl, C1-4 alkyloxyimino, NH2 optionally substituted by same or different 1 or ≥2 of C1-4 alkyl and C3-7 cycloalkyl, amino-C1-4 alkyl optionally N-substituted by same or different 1 or ≥2 of C1-4 alkyl and C3-7 cycloalkyl, oxo; or R7a and R7d represents a group which form a C3-5 cycloalkane ring together with the carbon atoms to which R7a and R7d are attached; some provisos are given] or esters or pharmacol. acceptable salts thereof. Thus, a THF soln. of 5-trityl-4,5,6,7-tetrahydrothieno[3,2-c]pyridine was treated with BuLi in hexane at -70° for 1 h and the with tributyltin chloride for 15 min to give 2-tributylstannyl-5-trityl-4,5,6,7-tetrahydrothieno[3,2-c]pyridine which was coupled with Et 8-chloro-1-cyclopropyl-9-methyl-4-oxo-4H-quinolizine-3-carboxylate in the presence of bis(triphenylphosphine)palladium(II) dichloride in toluene at 100° for 2 h to give 70% Et 1-cyclopropyl-9-methyl-4-oxo-8-(5-trityl-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)-4H-quinolizine-3-carboxylate (II). II was dissolved in THF and stirred with p-MeC6H4SO3H at room temp. for 7 h and at 40° for 4 h to give 91% Et 1-cyclopropyl-9-methyl-4-oxo-8-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)-4H-quinolizine-3-carboxylate p-toluenesulfonate which was stirred with a mixt. of satd. aq. NaHCO3 soln. and CHCl3 to give Et 1-cyclopropyl-9-methyl-4-oxo-8-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)-4H-quinolizine-3-carboxylate (III). III was sapond. by a mixt. of 1 N aq. NaOH soln., THF, and ethanol at room temp. for 6 h and neutralized with 1 N aq. HCl soln. to give 96% 1-cyclopropyl-9-methyl-4-oxo-8-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)-4H-quinolizine-3-carboxylic acid (IV). IV and 8-[4-amino-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl]-1-cyclopropyl-9-methyl-4-oxo-4H-quinolizine-3-carboxylic acid showed min. inhibitory concn. of 0.063 and ≤0.008 μg/mL, resp., against Staphylococcus aureus 209P. 8 Pharmaceutical formulations, e.g. a hard capsule contg. IV, were described.

IT **405141-13-1P 405141-14-2P 405141-15-3P**
405141-16-4P 405141-18-6P 405141-20-0P
405141-22-2P 405141-25-5P 405141-27-7P
405141-33-5P 405141-53-9P 405141-61-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxo-4H-quinolizinecarboxylic acid derivs. as antibacterial agents)

RN 405141-13-1 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid, 1-cyclopropyl-9-methyl-4-oxo-8-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 405141-14-2 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-9-methyl-4-oxo-8-(4,5,6,7-
tetrahydro-5-methylthieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 405141-15-3 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-9-methoxy-4-oxo-8-(4,5,6,7-
tetrahydrothieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 405141-16-4 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-7-fluoro-9-methyl-4-oxo-8-
(4,5,6,7-tetrahydro-4-methylthieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)





RN 405141-27-7 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-9-methyl-4-oxo-8-[4,5,6,7-
tetrahydro-6-(hydroxymethyl)thieno[3,2-c]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 405141-33-5 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-9-methyl-4-oxo-8-(4,5,6,7-
tetrahydro-7-methoxythieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 405141-53-9 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
8-(7-amino-4,5,6,7-tetrahydrothieno[3,2-
c]pyridin-2-yl)-1-cyclopropyl-9-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 405141-18-6 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-7-fluoro-9-methyl-4-oxo-8-
(4,5,6,7-tetrahydro-6-methylthieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 405141-20-0 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-9-methyl-4-oxo-8-(4,5,6,7-
tetrahydro-7-hydroxythieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 405141-22-2 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-7-fluoro-9-methyl-4-oxo-8-
(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 405141-25-5 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-9-(difluoromethoxy)-4-oxo-
8-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)

RN 405141-61-9 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid, 8-(7-amino-4,5,6,7-tetrahydro-5-
methylthieno[3,2-c]pyridin-2-yl)-1-cyclopropyl-9-methyl-4-oxo- (9CI) (CA INDEX NAME)



IT **405142-66-7P 405142-67-8P 405142-68-9P**
405142-70-3P 405142-71-4P 405142-73-6P
405142-77-0P 405142-79-2P 405142-80-5P
405142-89-4P 405142-91-8P 405143-02-4P
405143-05-7P 405143-22-8P 405143-27-3P
601525-62-6P 601525-64-8P 601525-65-9P
601525-66-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of oxo-4H-quinolizinecarboxylic acid derivs. as antibacterial
agents)

RN 405142-66-7 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-9-methyl-4-oxo-8-[4,5,6,7-
tetrahydro-5-(triphenylmethyl)thieno[3,2-c]pyridin-2-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 405142-67-8 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-9-methyl-4-oxo-8-(4,5,6,7-
tetrahydrothieno[3,2-c]pyridin-2-yl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 405142-68-9 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-9-methyl-4-oxo-8-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)-, ethyl ester, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 405142-67-8
CMF C23 H24 N2 O3 S



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



RN 405142-70-3 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-9-methoxy-4-oxo-8-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)-, ethyl ester, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 405142-69-0
CMF C23 H24 N2 O4 S



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



RN 405142-71-4 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-7-fluoro-9-methyl-4-oxo-8-[4,5,6,7-tetrahydro-4-methyl-5-(triphenylmethyl)thieno[3,2-c]pyridin-2-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 405142-73-6 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-7-fluoro-9-methyl-4-oxo-8-(4,5,6,7-tetrahydro-4-methylthieno[3,2-c]pyridin-2-yl)-, ethyl ester, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 405142-72-5
CMF C24 H25 F N2 O3 S



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



RN 405142-77-0 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-7-fluoro-9-methyl-4-oxo-8-[4,5,6,7-tetrahydro-6-methyl-5-(triphenylmethyl)thieno[3,2-c]pyridin-2-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 405142-79-2 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-7-fluoro-9-methyl-4-oxo-8-(4,5,6,7-tetrahydro-6-methylthieno[3,2-c]pyridin-2-yl)-, ethyl ester, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 405142-78-1
CMF C24 H25 F N2 O3 S



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



RN 405142-80-5 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-9-methyl-4-oxo-8-[4,5,6,7-tetrahydro-7-(methoxymethoxy)-5-(triphenylmethyl)thieno[3,2-c]pyridin-2-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 405142-89-4 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-9-(difluoromethoxy)-4-oxo-8-[4,5,6,7-tetrahydro-5-(triphenylmethyl)thieno[3,2-c]pyridin-2-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 405142-91-8 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-9-(difluoromethoxy)-4-oxo-
8-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)-, ethyl ester,
mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 405142-90-7
CMF C23 H22 F2 N2 O4 S



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



RN 405143-02-4 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-9-methyl-4-oxo-8-[4,5,6,7-
tetrahydro-7-methoxy-5-(triphenylmethyl)thieno[3,2-c]pyridin-2-yl]-,
ethyl
ester (9CI) (CA INDEX NAME)



RN 405143-05-7 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-9-methyl-4-oxo-8-(4,5,6,7-
tetrahydro-7-methoxythieno[3,2-c]pyridin-2-yl)-, ethyl ester,
mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 405143-04-6
CMF C24 H26 N2 O4 S



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



RN 405143-22-8 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-9-methyl-4-oxo-8-[4,5,6,7-
tetrahydro-5-(triphenylmethyl)-7-[(triphenylmethyl)amino]thieno[3,2-
c]pyridin-2-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 405143-27-3 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-9-methyl-4-oxo-8-[4,5,6,7-

tetrahydro-5-methyl-7-[(triphenylmethyl)amino]thieno[3,2-c]pyridin-2-yl]-,
ethyl ester (9CI) (CA INDEX NAME)



RN 601525-62-6 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-9-methoxy-4-oxo-8-[4,5,6,7-
tetrahydro-5-(triphenylmethyl)thieno[3,2-c]pyridin-2-yl]-, ethyl ester
(9CI) (CA INDEX NAME)



RN 601525-64-8 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-9-methyl-4-oxo-8-[4,5,6,7-
tetrahydro-7-(methoxymethoxy)thieno[3,2-c]pyridin-2-yl]-, ethyl ester,
mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 601525-63-7
CMF C25 H28 N2 O5 S



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



RN 601525-65-9 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-9-methyl-4-oxo-8-[4,5,6,7-

tetrahydro-6-(hydroxymethyl)-5-(triphenylmethyl)thieno[3,2-c]pyridin-2-yl]-
, ethyl ester (9CI) (CA INDEX NAME)



RN 601525-66-0 CAPLUS
CN Thieno[3,2-c]pyridine, 4,5,6,7-tetrahydro-6-[(methoxymethoxy)methyl]-2-
(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5-(triphenylmethyl)- (9CI)
(CA INDEX NAME)



ACCESSION NUMBER: 2003:282570 CAPLUS
DOCUMENT NUMBER: 138:304175
TITLE: Preparation of N-(azabicyclyl)arylamides for therapeutic use as nicotinic acetylcholine receptor agonists
INVENTOR(S): Walker, Daniel Patrick; Piotrowski, David W.; Jacobsen, Eric Jon; Acker, Brad A.; Wishka, Donn G.; Reitz, Steven Charles; Groppi, Vincent E., Jr.
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
SOURCE: PCT Int. Appl., 200 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003029252	A1	20030410	WO 2002-US29827	20021001
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2462453	AA	20030410	CA 2002-2462453	20021001
US 2003153595	A1	20030814	US 2002-262257	20021001
US 6911543	B2	20050628		
EP 1432707	A1	20040630	EP 2002-778286	20021001
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002013612	A	20040824	BR 2002-13612	20021001
JP 2005508932	T2	20050407	JP 2003-532500	20021001
US 2003176702	A1	20030918	US 2002-272802	20021017
US 6849620	B2	20050201		
BG 108650	A	20050430	BG 2004-108650	20040324
NO 2004001368	A	20040601	NO 2004-1368	20040401
US 2005222196	A1	20051006	US 2005-137912	20050526
US 2005234092	A1	20051020	US 2005-139066	20050526

PRIORITY APPLN. INFO.:
US 2001-326565P P 20011002
US 2001-326629P P 20011002
US 2001-334886P P 20011115
US 2001-339633P P 20011212
US 2002-262257 A1 20021001
WO 2002-US29827 W 20021001

OTHER SOURCE(S): MARPAT 138:304175
GI



II

AB N-(azabicyclyl)arylamides, such as RNR1C(:X)W [R = azabicyclyl; R1 = H, alkyl, cycloalkyl, haloalkyl, aryl; R2 = H, benzyl, alkyl, haloalkyl, cycloalkyl, aryl; W = heteroaryl; X = O, S], were prepared for therapeutic use as nicotinic acetylcholine receptor agonists. These amides are useful for the treatment of central nervous system disorders, such as cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (mild cognitive impairment), senile dementia, schizophrenia, psychosis, attention deficit disorder, attention deficit hyperactivity disorder, mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain injury, behavioral and cognitive problems associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntington's disease, depression, general anxiety disorder, age-related macular degeneration, Parkinson's disease, tardive dyskinesia, Pick's disease, post traumatic stress disorder, dysregulation of food intake including bulimia and anorexia nervosa, withdrawal symptoms associated with smoking cessation and dependent drug cessation, Gilles de la Tourette's Syndrome, glaucoma, neurodegeneration associated with glaucoma, or symptoms associated with pain. Thus, the fumarate salt of amide II was prepared via a multistep synthetic sequence which included intramol. cyclization of trans-3-(tert-butoxycarbonylamino)-4-(2-hydroxyethyl)-1-phenylmethylpyrrolidine to form exo-3-(tert-butoxycarbonylamino)-1-azabicyclo[2.2.1]heptane, which contains the target azabicyclic ring, and subsequent amidation of the the corresponding azabicyclic amine with furo[2,3-c]pyridine-5-carboxylic acid. The prepared amides were assayed for human α7-5HT3 receptor binding activity.
IT **508206-50-6P 508206-51-7P 508206-52-8P 508206-53-9P 508206-54-0P 508206-55-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-(azabicyclyl)arylamides for therapeutic use as nicotinic acetylcholine receptor agonists)
RN 508206-50-6 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 508206-51-7 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-2-(1-piperidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 508206-52-8 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 508206-53-9 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-2-(4-thiomorpholinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 508206-54-0 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide,
N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-
yl-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 508206-55-1 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide,
N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-
yl-2-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L6 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:221697 CAPLUS
DOCUMENT NUMBER: 138:238006
TITLE: Preparation of N-[7-aza[2.2.1]bicycloheptanyl]arylamides for therapeutic use as nicotinic acetylcholine receptor agonists
INVENTOR(S): Wishka, Donn G.; Walker, Daniel Patrick; Corbett, Jeffrey W.; Reitz, Steven Charles; Rauckhorst, Mark R.; Groppi, Vincent E., Jr.
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
SOURCE: PCT Int. Appl., 224 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003022856	A1	20030320	WO 2002-US25959	20020904
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2460075	AA	20030320	CA 2002-2460075	20020904
US 2003105089	A1	20030605	US 2002-234575	20020904
EP 1425286	A1	20040609	EP 2002-757132	20020904
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002012477	A	20040824	BR 2002-12477	20020904
JP 2005527472	T2	20050915	JP 2003-526930	20020904
PRIORITY APPLN. INFO.:			US 2001-322100P P	20010912
			US 2001-322333P P	20010912
			US 2001-322346P P	20010912
			US 2002-399530P P	20020730
			WO 2002-US25959 W	20020904

OTHER SOURCE(S): MARPAT 138:238006
GI



I II

AB 7-Aza[2.2.1]bicycloheptane derivs., such as amides I [R1 = H, alkyl, cycloalkyl, haloalkyl, aryl; R2 = H, benzyl, alkyl, haloalkyl, cycloalkyl, aryl; W = heteroaryl; X = O, S], were prepared for therapeutic use as nicotinic acetylcholine receptor agonists. These amides are useful for the treatment of central nervous system disorders, such as cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (mild cognitive impairment), senile dementia, schizophrenia, psychosis, attention deficit disorder, attention deficit hyperactivity disorder, mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain injury, behavioral and cognitive problems associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntington's disease, depression, general anxiety disorder, age-related macular degeneration, Parkinson's disease, tardive dyskinesia, Pick's disease, post traumatic stress disorder, dysregulation of food intake including bulimia and anorexia nervosa, withdrawal symptoms associated with smoking cessation and dependent drug cessation, Gilles de la Tourette's Syndrome, glaucoma, neurodegeneration associated with glaucoma, or symptoms associated with pain. Thus, amide dihydrochloride II was prepared via a multistep synthetic sequence which included cycloaddn. of N-tert-butoxycarbonylpyrrole with BrC.tplbond.CCO2Me to form the azabicyclic ring, and subsequent amidation reaction of tert-Bu (1S,2R,4R)-2-amino-7-azabicyclo[2.2.1]heptane-7-carboxylate with 3-methylfuro[2,3-c]pyridine-5-carboxylic acid. The prepared amides were assayed for human α7-5HT3 receptor binding activity.

IT **501900-45-4P 501900-46-5P 501900-47-6P 501900-48-7P 501900-49-8P 501900-50-1P 501900-51-2P 501900-52-3P 501900-53-4P 501900-54-5P 501900-55-6P 501900-56-7P 501900-57-8P 501900-58-9P 501900-61-4P 501900-62-5P 501900-63-6P 501900-64-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-[7-aza[2.2.1]bicycloheptanyl]arylamides for therapeutic use as nicotinic acetylcholine receptor agonists)

RN 501900-45-4 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide,
N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-
2-yl-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 501900-46-5 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide,
N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-
2-yl-2-(2-oxo-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501900-47-6 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide,
N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-
2-yl-2-(1-piperidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501900-48-7 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide,
N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-
2-yl-2-(2-oxo-1-piperidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501900-49-8 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide,
N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-
2-yl-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501900-50-1 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide,
N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-
2-yl-2-(3-oxo-4-morpholinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501900-51-2 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide,
N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-
2-yl-2-(4-thiomorpholinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501900-52-3 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide,
N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-
2-yl-2-(3-oxo-4-thiomorpholinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501900-53-4 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide,
N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-
2-yl-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501900-54-5 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide,
N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-
2-yl-2-(2-oxo-1-piperazinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501900-55-6 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide,
N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-
2-yl-2-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501900-56-7 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide,
N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-
2-yl-2-(4-methyl-2-oxo-1-piperazinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501900-57-8 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide,
N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-
2-yl-2-(3-oxo-1-piperazinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501900-58-9 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide,
N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-
2-yl-2-(4-methyl-3-oxo-1-piperazinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501900-61-4 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide,
N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-
2-yl-2-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501900-62-5 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide,
N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-
2-yl-2-(1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 501900-63-6 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide,
N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-
2-yl-2-(1H-1,2,4-triazol-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501900-64-7 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide,
N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-
2-yl-2-(1H-1,2,3-triazol-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L6 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:964353 CAPLUS
DOCUMENT NUMBER: 138:24865
TITLE: Preparation and formulation of N-quinuclidinyl-heteroaryls as nicotinic acetylcholinergic receptor modulators for the treatment of a variety of central nervous system disorders
INVENTOR(S): Wishka, Donn G.; Reitz, Steven C.; Piotrowski, David W.; Groppi, Vincent E., Jr.
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
SOURCE: PCT Int. Appl., 262 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002100857	A1	20021219	WO 2002-US16568	20020606
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2445467	AA	20021219	CA 2002-2445467	20020606
US 2003045540	A1	20030306	US 2002-163564	20020606
EP 1406901	A1	20040414	EP 2002-778932	20020606
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002010384	A	20040629	BR 2002-10384	20020606
CN 1511154	A	20040707	CN 2002-809814	20020606
JP 2004537532	T2	20041216	JP 2003-503624	20020606
ZA 2003008844	A	20040628	ZA 2003-8844	20031113
PRIORITY APPLN. INFO.:			US 2001-297708P	P 20010612
			US 2001-297709P	P 20010612
			US 2001-297710P	P 20010612
			US 2001-297711P	P 20010612
			US 2001-297712P	P 20010612
			US 2001-328596P	P 20011011
			US 2002-373495P	P 20020418
			WO 2002-US16568	W 20020606

OTHER SOURCE(S): MARPAT 138:24865
GI

L6 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I II

AB N-quinuclidinyl-heteroaryls, such as amides I [R1 = H, alkyl, cycloalkyl, haloalkyl, aryl; R2 = H, benzyl, alkyl, haloalkyl, cycloalkyl, aryl; W = heteroaryl; X = O, S], were prepared for therapeutic use in the treatment of central nervous system disorders, such as cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (mild cognitive impairment), senile dementia, schizophrenia, psychosis, attention deficit disorder, attention deficit hyperactivity disorder, mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain injury, behavioral and cognitive problems associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntington's disease, depression, general anxiety disorder, age-related macular degeneration, Parkinson's disease, tardive dyskinesia, Pick's disease, post traumatic stress disorder, dysregulation of food intake including bulimia and anorexia nervosa, withdrawal symptoms associated with smoking cessation and dependent drug cessation, Gilles de la Tourette's Syndrome, glaucoma, neurodegeneration associated with glaucoma, or symptoms associated with pain. Thus, (3R)-N-quinuclidinyl amide II was prepared via a multistep synthetic sequence which started from 2-chloro-3-pyridinol and which included intramol. cyclization of 2-chloro-6-(hydroxymethyl)-4-[(trimethylsilyl)ethynyl]-3-pyridinol to form (7-chlorofuro[2,3-c]pyridin-5-yl)methanol in 27% yield using Et3N in EtOH, elaboration of the alc. to 2,3-dihydrofuro[2,3-c]pyridine-5-carboxylic acid, and, finally, amidation of the acid with (R)-(+)-3-aminoquinuclidine. The prepared quinuclidine derivs. were assayed for nicotinic acetylcholinergic receptor binding activity using brain cell membrane prepared from male Sprague-Dawley rats.

IT **478151-66-5P 478151-67-6P 478151-68-7P**
478151-69-8P 478151-70-1P 478151-71-2P
478151-72-3P 478151-73-4P 478151-74-5P
478151-75-6P 478151-76-7P 478151-77-8P
478151-78-9P 478151-79-0P 478151-82-5P
478151-83-6P 478151-84-7P 478151-85-8P
478152-32-8P 478152-33-9P 478152-34-0P
478152-35-1P 478152-36-2P 478152-37-3P
478152-38-4P 478152-39-5P 478152-40-8P
478152-41-9P 478152-42-0P 478152-43-1P
478152-44-2P 478152-45-3P 478152-48-6P
478152-49-7P 478152-50-0P 478152-51-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and formulation of N-quinuclidinyl-heteroaryl amides as

L6 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
nicotinic acetylcholinergic receptor modulators for treatment of a variety of central nervous system disorders)

RN 478151-66-5 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide,
N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-2-
(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478151-67-6 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide,
N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-2-
(2-oxo-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478151-68-7 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide,
N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-2-
(1-piperidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478151-69-8 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide,
N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-2-
(2-oxo-1-piperidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478151-70-1 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide,
N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-2-
(4-morpholinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478151-71-2 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide,
N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-2-
(3-oxo-4-morpholinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478151-72-3 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide,
N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-2-
(4-thiomorpholinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478151-73-4 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide,
N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-2-
(3-oxo-4-thiomorpholinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478151-74-5 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide,
N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-2-
(1-piperazinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478151-75-6 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide,
N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-2-
(2-oxo-1-piperazinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478151-76-7 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide,
N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-2-
(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478151-77-8 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide,
N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-2-
(4-methyl-2-oxo-1-piperazinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478151-78-9 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide,
N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-2-
(3-oxo-1-piperazinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478151-79-0 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide,
N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-2-
(4-methyl-3-oxo-1-piperazinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478151-82-5 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide,
N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-2-
(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478151-83-6 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide,
N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-2-
(1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478151-84-7 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide,
N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-2-
(1H-1,2,4-triazol-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478151-85-8 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-2-(1H-1,2,3-triazol-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478152-32-8 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide, N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478152-33-9 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide, N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-2-(2-oxo-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 478152-38-4 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide, N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-2-(4-thiomorpholinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478152-39-5 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide, N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-2-(3-oxo-4-thiomorpholinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478152-40-8 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide, N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478152-34-0 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide, N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-2-(1-piperidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478152-35-1 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide, N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-2-(2-oxo-1-piperidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478152-36-2 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide, N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478152-37-3 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide, N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-2-(3-oxo-4-morpholinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 478152-41-9 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide, N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-2-(2-oxo-1-piperazinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478152-42-0 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide, N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-2-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478152-43-1 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide, N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-2-(4-methyl-2-oxo-1-piperazinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478152-44-2 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide, N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-2-(3-oxo-1-piperazinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478152-45-3 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide, N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-2-(4-methyl-3-oxo-1-piperazinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478152-48-6 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide, N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-2-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478152-49-7 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide, 2-(1H-imidazol-1-yl)-N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478152-50-0 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide, N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-2-(1H-1,2,4-triazol-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478152-51-1 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide, N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-2-(1H-1,2,3-triazol-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2002:315475 CAPLUS
DOCUMENT NUMBER: 136:340597
TITLE: Preparation of quinoline- and naphthyridinecarboxylic acid antibacterials
INVENTOR(S): Elmore, Steven W.; Cooper, Curt S.; Schultz, Colleen C.; Hutchinson, Douglas K.; Donner, Pamela L.; Green, Brian E.; Anderson, David D.; Xie, Qinghua; Dinges, Jurgen; Lynch, Linda M.; Pratt, John K.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 222 pp., Cont.-in-part of U. S. Ser. No. 705,332.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2002049223	A1	20020425	US 2001-850664		20010507
PRIORITY APPLN. INFO.:			US 1999-163920P	P	19991105
			US 2000-705332	A2	20001103

OTHER SOURCE(S): MARPAT 136:340597
GI



I



II

AB Title compds. I [A1 = N, (un)substituted CH; A2 = S, O, (un)substituted NH; R1, R15 = H, alkyl, halo, NO2, (un)protected NH2; Z = N, (un)substituted CH; R3 = (un)substituted alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocyclic; R4 = H, (un)substituted OH; R4R5 = atoms

required to complete an (un)substituted carbocycle or heterocycle] and their pharmaceutically acceptable salts, were prepd. for use as antibacterial agents. Thus, 2-thienylethylamine was methylenated and cyclized to 4,5,6,7-tetrahydrothieno[3,2-c]pyridine which was tritylated in the 5-position, tributylstannylated, and treated with Et 7-bromo-1-cyclopropyl-8-methoxy-4-oxo-1,4-dihydro-3-quinolinecarboxylate, followed by ester hydrolysis to give the title compd. II. II had an min. inhibitor concn. against Staphylococcus aureus ATCC 6538P of 0.05 mg/mL.

IT 339050-55-4P 339050-56-5P 339050-57-6P
339050-58-7P 339050-59-8P 339050-65-6P
339050-66-7P 339050-67-8P 339050-68-9P
339050-69-0P 339050-70-3P 339050-71-4P
339050-72-5P 339050-73-6P 339050-74-7P
339050-78-1P 339050-79-2P 339050-80-5P
339050-81-6P 339050-82-7P 339053-35-9P
339053-36-0P 339053-40-6P 339053-52-0P
339053-55-3P 339053-56-4P 339053-92-8P
339053-93-9P 339053-94-0P 339053-95-1P
339053-96-2P 339054-02-3P 339054-03-4P
339054-04-5P 339054-05-6P 339054-06-7P
339054-07-8P 339054-08-9P 339054-09-0P
339054-10-3P 339054-11-4P 339054-15-8P
339054-16-9P 339054-17-0P 339054-18-1P
339054-19-2P 339054-67-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinoline- and naphthyridinecarboxylic acid antibacterials)

RN 339050-55-4 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 339050-56-5 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-7-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 339050-57-6 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 339050-58-7 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 339050-59-8 CAPLUS



●x HBr

RN 339050-67-8 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydro-6-methylthieno[3,2-c]pyridin-2-yl)-, hydrobromide (9CI) (CA INDEX NAME)



●x HBr

RN 339050-68-9 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-8-(difluoromethoxy)-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydro-6-methylthieno[3,2-c]pyridin-2-yl)-, hydrobromide (9CI) (CA INDEX NAME)



●x HBr

RN 339050-69-0 CAPLUS

CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-8-(difluoromethoxy)-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 339050-65-6 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydro-6-methylthieno[3,2-c]pyridin-2-yl)-, hydrobromide (9CI) (CA INDEX NAME)



●x HBr

RN 339050-66-7 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydro-6-methylthieno[3,2-c]pyridin-2-yl)-, hydrobromide (9CI) (CA INDEX NAME)

CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-7-(4,5,6,7-tetrahydro-6-methylthieno[3,2-c]pyridin-2-yl)-, hydrobromide (9CI) (CA INDEX NAME)



●x HBr

RN 339050-70-3 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydro-4-methylthieno[3,2-c]pyridin-2-yl)-, hydrobromide (9CI) (CA INDEX NAME)



●x HBr

RN 339050-71-4 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydro-4-methylthieno[3,2-c]pyridin-2-yl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 339050-72-5 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydro-4-methylthieno[3,2-c]pyridin-2-yl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 339050-73-6 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-7-(4,5,6,7-tetrahydro-4-methylthieno[3,2-c]pyridin-2-yl)-, hydrobromide (9CI) (CA INDEX NAME)



●x HBr



●x HBr

RN 339050-80-5 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-7-(4,5,6,7-tetrahydro-7,7-dimethylthieno[3,2-c]pyridin-2-yl)-, hydrobromide (9CI) (CA INDEX NAME)



●x HBr

RN 339050-81-6 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydro-7,7-dimethylthieno[3,2-c]pyridin-2-yl)-, hydrobromide (9CI) (CA INDEX NAME)



●x HBr

RN 339050-82-7 CAPLUS

RN 339050-74-7 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-8-(difluoromethoxy)-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydro-4-methylthieno[3,2-c]pyridin-2-yl)-, hydrobromide (9CI) (CA INDEX NAME)



●x HBr

RN 339050-78-1 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydro-7,7-dimethylthieno[3,2-c]pyridin-2-yl)-, hydrobromide (9CI) (CA INDEX NAME)



●x HBr

RN 339050-79-2 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydro-7,7-dimethylthieno[3,2-c]pyridin-2-yl)-, hydrobromide (9CI) (CA INDEX NAME)

CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-8-(difluoromethoxy)-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydro-7,7-dimethylthieno[3,2-c]pyridin-2-yl)-, hydrobromide (9CI) (CA INDEX NAME)



●x HBr

RN 339053-35-9 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-7-(4,5,6,7-tetrahydro-7-hydroxythieno[3,2-c]pyridin-2-yl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 339053-36-0 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-7-(4,5,6,7-tetrahydro-7-oxothieno[3,2-c]pyridin-2-yl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 339053-40-6 CAPLUS
CN 3-Quinolinecarboxylic acid, 7-(7-amino-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo- (9CI) (CA INDEX NAME)



RN 339053-52-0 CAPLUS
CN 3-Quinolinecarboxylic acid, 7-(7-azido-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo- (9CI) (CA INDEX NAME)



RN 339053-55-3 CAPLUS
CN 3-Quinolinecarboxylic acid, 7-(5-acetyl-7-amino-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo- (9CI) (CA INDEX NAME)



RN 339053-56-4 CAPLUS
CN 3-Quinolinecarboxylic acid, 7-[7-amino-4,5,6,7-tetrahydro-5-(methylsulfonyl)thieno[3,2-c]pyridin-2-yl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo- (9CI) (CA INDEX NAME)



RN 339053-92-8 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 339053-93-9 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-7-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 339053-94-0 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 339053-95-1 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 339053-96-2 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-8-(difluoromethoxy)-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 339054-02-3 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydro-6-methylthieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 339054-03-4 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydro-6-methylthieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 339054-04-5 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydro-6-methylthieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 339054-05-6 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-8-(difluoromethoxy)-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydro-6-methylthieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 339054-06-7 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-7-(4,5,6,7-tetrahydro-6-methylthieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 339054-07-8 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydro-4-methylthieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 339054-08-9 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydro-4-methylthieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 339054-09-0 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydro-4-methylthieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 339054-10-3 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-7-(4,5,6,7-tetrahydro-4-methylthieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 339054-11-4 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-8-(difluoromethoxy)-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydro-4-methylthieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 339054-15-8 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydro-7,7-dimethylthieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 339054-16-9 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydro-7,7-dimethylthieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 339054-17-0 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-7-(4,5,6,7-tetrahydro-7,7-dimethylthieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 339054-18-1 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydro-7,7-dimethylthieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 339054-19-2 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-8-(difluoromethoxy)-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydro-7,7-dimethylthieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 339054-67-0 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-7-(4,5,6,7-tetrahydro-7-oxothieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



IT **339057-00-0 339057-01-1 339057-05-5**
339057-15-7 339057-18-0 339057-19-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of quinoline- and naphthyridinecarboxylic acid antibacterials)
RN 339057-00-0 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-7-[5-[(1,1-dimethylethoxy)carbonyl]-4,5,6,7-tetrahydro-7-hydroxythieno[3,2-c]pyridin-2-yl]-1,4-dihydro-8-methoxy-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 339057-01-1 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-7-[5-[(1,1-dimethylethoxy)carbonyl]-4,5,6,7-tetrahydro-7-oxothieno[3,2-c]pyridin-2-yl]-1,4-dihydro-8-methoxy-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 339057-05-5 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-7-[5-[(1,1-dimethylethoxy)carbonyl]-7-[[(1,1-dimethylethoxy)carbonyl]amino]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl]-1,4-dihydro-8-methoxy-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 339057-15-7 CAPLUS
CN 3-Quinolinecarboxylic acid, 7-[7-azido-5-[(1,1-dimethylethoxy)carbonyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 339057-18-0 CAPLUS
CN 3-Quinolinecarboxylic acid, 7-[5-acetyl-7-[[(1,1-dimethylethoxy)carbonyl]amino]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo- (9CI) (CA INDEX NAME)



RN 339057-19-1 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-7-[7-[[(1,1-dimethylethoxy)carbonyl]amino]-4,5,6,7-tetrahydro-5-(methylsulfonyl)thieno[3,2-c]pyridin-2-yl]-1,4-dihydro-8-methoxy-4-oxo- (9CI) (CA INDEX NAME)



IT **339054-93-2P 339054-94-3P 339054-95-4P**
339054-97-6P 339054-98-7P 339054-99-8P
339055-00-4P 339055-01-5P 339055-12-8P
339055-13-9P 339055-14-0P 339055-15-1P
339055-16-2P 339055-17-3P 339055-18-4P
339055-19-5P 339055-23-1P 339055-24-2P
339055-25-3P 339055-26-4P 339055-27-5P
339055-38-8P 339055-39-9P 339055-40-2P
339055-41-3P 339055-42-4P 339055-43-5P
339056-36-9P 339056-37-0P 339056-38-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of quinoline- and naphthyridinecarboxylic acid antibacterials)
RN 339054-93-2 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-[4,5,6,7-tetrahydro-5-(triphenylmethyl)thieno[3,2-c]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 339054-94-3 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-7-[4,5,6,7-tetrahydro-5-(triphenylmethyl)thieno[3,2-c]pyridin-2-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 339054-95-4 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-7-[4,5,6,7-tetrahydro-5-(triphenylmethyl)thieno[3,2-c]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 339054-97-6 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-[4,5,6,7-tetrahydro-5-(triphenylmethyl)thieno[3,2-c]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 339054-98-7 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[4,5,6,7-tetrahydro-5-(triphenylmethyl)thieno[3,2-c]pyridin-2-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 339054-99-8 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid,
1-cyclopropyl-6-fluoro-1,4-dihydro-4-
oxo-7-[4,5,6,7-tetrahydro-5-(triphenylmethyl)thieno[3,2-c]pyridin-2-yl]-
(9CI) (CA INDEX NAME)



RN 339055-00-4 CAPLUS
CN 3-Quinolinecarboxylic acid,
1-cyclopropyl-8-(difluoromethoxy)-1,4-dihydro-

4-oxo-7-[4,5,6,7-tetrahydro-5-(triphenylmethyl)thieno[3,2-c]pyridin-2-yl]-
, ethyl ester (9CI) (CA INDEX NAME)



RN 339055-01-5 CAPLUS
CN 3-Quinolinecarboxylic acid,
1-cyclopropyl-8-(difluoromethoxy)-1,4-dihydro-

4-oxo-7-[4,5,6,7-tetrahydro-5-(triphenylmethyl)thieno[3,2-c]pyridin-2-yl]-
(9CI) (CA INDEX NAME)



RN 339055-15-1 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid,
1-cyclopropyl-6-fluoro-1,4-dihydro-4-
oxo-7-[4,5,6,7-tetrahydro-6-methyl-5-[(phenylmethoxy)carbonyl]thieno[3,2-
c]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 339055-16-2 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-[4,5,6,7-

tetrahydro-6-methyl-5-[(phenylmethoxy)carbonyl]thieno[3,2-c]pyridin-2-yl]-
(9CI) (CA INDEX NAME)



RN 339055-17-3 CAPLUS
CN 3-Quinolinecarboxylic acid,
1-cyclopropyl-8-(difluoromethoxy)-1,4-dihydro-

4-oxo-7-[4,5,6,7-tetrahydro-6-methyl-5-[(phenylmethoxy)carbonyl]thieno[3,2-
c]pyridin-2-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 339055-12-8 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-
[4,5,6,7-tetrahydro-6-methyl-5-[(phenylmethoxy)carbonyl]thieno[3,2-
c]pyridin-2-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 339055-13-9 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-
[4,5,6,7-tetrahydro-6-methyl-5-[(phenylmethoxy)carbonyl]thieno[3,2-
c]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 339055-14-0 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid,
1-cyclopropyl-6-fluoro-1,4-dihydro-4-
oxo-7-[4,5,6,7-tetrahydro-6-methyl-5-[(phenylmethoxy)carbonyl]thieno[3,2-
c]pyridin-2-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 339055-18-4 CAPLUS
CN 3-Quinolinecarboxylic acid,
1-cyclopropyl-8-(difluoromethoxy)-1,4-dihydro-

4-oxo-7-[4,5,6,7-tetrahydro-6-methyl-5-[(phenylmethoxy)carbonyl]thieno[3,2-
c]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 339055-19-5 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-7-
[4,5,6,7-tetrahydro-6-methyl-5-[(phenylmethoxy)carbonyl]thieno[3,2-
c]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 339055-23-1 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-[4,5,6,7-

tetrahydro-4-methyl-5-[(phenylmethoxy)carbonyl]thieno[3,2-c]pyridin-2-yl]-
(9CI) (CA INDEX NAME)



RN 339055-24-2 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-[4,5,6,7-tetrahydro-4-methyl-5-[(phenylmethoxy)carbonyl]thieno[3,2-c]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 339055-25-3 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[4,5,6,7-tetrahydro-4-methyl-5-[(phenylmethoxy)carbonyl]thieno[3,2-c]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 339055-26-4 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-7-[4,5,6,7-tetrahydro-4-methyl-5-[(phenylmethoxy)carbonyl]thieno[3,2-c]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 339055-40-2 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-7-[4,5,6,7-tetrahydro-7,7-dimethyl-5-[(phenylmethoxy)carbonyl]thieno[3,2-c]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 339055-41-3 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[4,5,6,7-tetrahydro-7,7-dimethyl-5-[(phenylmethoxy)carbonyl]thieno[3,2-c]pyridin-2-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 339055-42-4 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[4,5,6,7-tetrahydro-7,7-dimethyl-5-[(phenylmethoxy)carbonyl]thieno[3,2-c]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 339055-27-5 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-8-(difluoromethoxy)-1,4-dihydro-4-oxo-7-[4,5,6,7-tetrahydro-4-methyl-5-[(phenylmethoxy)carbonyl]thieno[3,2-c]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 339055-38-8 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-[4,5,6,7-tetrahydro-7,7-dimethyl-5-[(phenylmethoxy)carbonyl]thieno[3,2-c]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 339055-39-9 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-[4,5,6,7-tetrahydro-7,7-dimethyl-5-[(phenylmethoxy)carbonyl]thieno[3,2-c]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 339055-43-5 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-8-(difluoromethoxy)-1,4-dihydro-4-oxo-7-[4,5,6,7-tetrahydro-7,7-dimethyl-5-[(phenylmethoxy)carbonyl]thieno[3,2-c]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 339056-36-9 CAPLUS
CN 3-Quinolinecarboxylic acid, 7-(7-azido-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 339056-37-0 CAPLUS
CN 3-Quinolinecarboxylic acid, 7-(5-acetyl-7-azido-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)

L6 ANSWER 11 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 339056-38-1 CAPLUS
CN 3-Quinolinecarboxylic acid, 7-[7-azido-4,5,6,7-tetrahydro-5-(methylsulfonyl)thieno[3,2-c]pyridin-2-yl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)



L6 ANSWER 12 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:220590 CAPLUS
DOCUMENT NUMBER: 136:263150
TITLE: Preparation of 8-aryl or heteroaryl-4-oxo-4H-quinolizine-3-carboxylic acid derivatives as antibacterial agents
INVENTOR(S): Ohya, Satoshi; Masuda, Nobuhisa; Kuroki, Yoshiaki; Inoue, Teruhiko; Okudo, Makoto; Iwata, Toshihide; Kokubo, Koji; Mizuno, Gen; Hagihara, Masahiko
PATENT ASSIGNEE(S): Sankyo Company, Ltd., Japan; Ube Industries,ltd.
SOURCE: PCT Int. Appl., 332 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022614	A1	20020321	WO 2001-JP7842	20010910
W: AU, BR, CA, CN, CO, CZ, HU, ID, IL, IN, KR, MX, NO, NZ, PL, RU, SG, SK, US, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
AU 2001086191	A5	20020326	AU 2001-86191	20010910
JP 2002179678	A2	20020626	JP 2001-274528	20010911

PRIORITY APPLN. INFO.: JP 2000-275840 A 20000912
JP 2000-301812 A 20001002
WO 2001-JP7842 W 20010910

OTHER SOURCE(S): MARPAT 136:263150
GI



AB Compds. of the general formula (I; R1 = H, optionally 1 or ≥2 halo-substituted C1-6 alkyl or C3-7 cycloalkyl, optionally 1 or ≥2 halo or amino-substituted aryl or heteroaryl; R2 = H, halo, cyano, HO, 1 or 2≥ halo-substituted C1-6 alkyl or alkoxy; R3 = H, halo (provided that R3 is only halo, when the ring formed by the Ph ring and the ring G in Q1 of R5 is an isoindoline ring); R5 = Q, Q1; wherein ring A = heteroaryl ring; ring G = C5-8 cycloalkene ring with optionally a carbon atom being replaced by N, O, or S atom, C5-8 cycloalkane ring; R6a, R6c = H, halo, HO, NO2, NH2, cyano, optionally 1 or ≥2 halo-substituted C1-4 alkyl or alkoxy; R7a, R7d = H, halo, HO, NO2, cyano, hydroxyimino, optionally 1 or ≥2 halo-substituted C1-4 alkyl or alkoxy,

L6 ANSWER 12 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

hydroxy-C1-4 alkyl, C1-4 alkyloxyimino, NH2 or amino-C1-4 alkyl optionally
N-substituted by 1 or 2≥ substituents selected from C1-4 alkyl and C3-7 cycloalkyl, a group forming a C3-5 cycloalkane ring together with oxo
or a carbon atom to which it is attached; provided that the condensed ring
formed by the Ph ring and the G ring in Q1 is not a tetrahydroisoquinoline
ring], esters thereof, or pharmacol. acceptable salts thereof, are prepd. Thus, a soln. of 0.98 g 4-(tert-butoxycarbonylamino)-6-tert-butoxycarbonyl-7,7-dimethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine in 40 mL THF was treated dropwise with 7.7 mL 1.0 M s-butyllithium/hexane at ≤70° over 5 min, stirred for 30 min at the same temp., treated dropwise with 0.86 mL tri-Me borate, stirred for 30 min to give 1.12 g [4-(tert-butoxycarbonylamino)-6-tert-butoxycarbonyl-7,7-dimethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl]boronic acid di-Me ester which was treated with 34 mL toluene/EtOH (7/3) and 1.7 mL 2 M aq. Na2CO3 and then with 0.55 g Et 8-chloro-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-4H-quinolizine-3-carboxylate and 0.26 g tetrakis(triphenylphosphine)palladium (0), and stirred at 80° for 3 h to give 82% Et 8-[4-(tert-butoxycarbonylamino)-6-tert-butoxycarbonyl-7,7-dimethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl]-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-4H-quinolizine-3-carboxylate (II). II (0.92 g) was treated with 5 mL 1 N aq. NaOH and 5 mL ethanol, and stirred at room temp. for 4 hand acidified with 1 N aq. HCl to nearly quant. give 8-(4-(tert-butoxycarbonylamino)-6-tert-butoxycarbonyl-7,7-dimethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl]-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-4H-quinolizine-3-carboxylic acid which (0.94 g) was added to 60 mL CH2Cl2, treated with HCl(g) under ice-cooling, and stirred at room temp. for 1 h to give 8-(4-amino-6-carboxy-7,7-dimethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-4H-quinolizine-3-carboxylic acid (III) dihydrochloride. III.2HCl was converted into free amine III. III showed min. inhibitory concn. of ≤0.008 μg/mL against Staphylococcus aureus 209P. Pharmaceutical formulations contg. I were also prepd.

IT **405141-13-1P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 8-aryl or heteroaryl-4-oxo-4H-quinolizinecarboxylic acid derivs. as antibacterial agents)

RN 405141-13-1 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid, 1-cyclopropyl-9-methyl-4-oxo-8-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 12 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT **405141-14-2P 405141-15-3P 405141-16-4P**
405141-18-6P 405141-20-0P 405141-22-2P
405141-25-5P 405141-27-7P 405141-33-5P
405141-53-9P 405141-61-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 8-aryl or heteroaryl-4-oxo-4H-quinolizinecarboxylic acid derivs. as antibacterial agents)

RN 405141-14-2 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid, 1-cyclopropyl-9-methyl-4-oxo-8-(4,5,6,7-tetrahydro-5-methylthieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 405141-15-3 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid, 1-cyclopropyl-9-methoxy-4-oxo-8-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 405141-16-4 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid, 1-cyclopropyl-7-fluoro-9-methyl-4-oxo-8-(4,5,6,7-tetrahydro-4-methylthieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 405141-18-6 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-7-fluoro-9-methyl-4-oxo-8-
(4,5,6,7-tetrahydro-6-methylthieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 405141-20-0 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-9-methyl-4-oxo-8-(4,5,6,7-
tetrahydro-7-hydroxythieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 405141-22-2 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-7-fluoro-9-methyl-4-oxo-8-
(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 405141-25-5 CAPLUS



RN 405141-61-9 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid, 8-(7-amino-4,5,6,7-tetrahydro-5-
methylthieno[3,2-c]pyridin-2-yl)-1-cyclopropyl-9-methyl-4-oxo- (9CI) (CA INDEX NAME)



IT **405142-66-7P 405142-67-8P 405142-68-9P**
405142-69-0P 405142-70-3P 405142-71-4P
405142-73-6P 405142-77-0P 405142-79-2P
405142-80-5P 405142-81-6P 405142-82-7P
405142-89-4P 405142-91-8P 405142-95-2P
405142-96-3P 405142-98-5P 405143-02-4P
405143-05-7P 405143-22-8P 405143-27-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 8-aryl or heteroaryl-4-oxo-4H-quinolizinecarboxylic acid
derivs. as antibacterial agents)
RN 405142-66-7 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-9-methyl-4-oxo-8-[4,5,6,7-
tetrahydro-5-(triphenylmethyl)thieno[3,2-c]pyridin-2-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 405142-67-8 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-9-methyl-4-oxo-8-(4,5,6,7-

CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-9-(difluoromethoxy)-4-oxo-
8-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 405141-27-7 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-9-methyl-4-oxo-8-[4,5,6,7-
tetrahydro-6-(hydroxymethyl)thieno[3,2-c]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 405141-33-5 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-9-methyl-4-oxo-8-(4,5,6,7-
tetrahydro-7-methoxythieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 405141-53-9 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
8-(7-amino-4,5,6,7-tetrahydrothieno[3,2-
c]pyridin-2-yl)-1-cyclopropyl-9-methyl-4-oxo- (9CI) (CA INDEX NAME)

tetrahydrothieno[3,2-c]pyridin-2-yl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 405142-68-9 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-9-methyl-4-oxo-8-(4,5,6,7-
tetrahydrothieno[3,2-c]pyridin-2-yl)-, ethyl ester, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 405142-67-8
CMF C23 H24 N2 O3 S



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



RN 405142-69-0 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-9-methoxy-4-oxo-8-(4,5,6,7-
tetrahydrothieno[3,2-c]pyridin-2-yl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 405142-70-3 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-9-methoxy-4-oxo-8-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)-, ethyl ester, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 405142-69-0
CMF C23 H24 N2 O4 S



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



RN 405142-71-4 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-7-fluoro-9-methyl-4-oxo-8-

[4,5,6,7-tetrahydro-4-methyl-5-(triphenylmethyl)thieno[3,2-c]pyridin-2-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 405142-73-6 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-7-fluoro-9-methyl-4-oxo-8-(4,5,6,7-tetrahydro-4-methylthieno[3,2-c]pyridin-2-yl)-, ethyl ester, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 405142-72-5
CMF C24 H25 F N2 O3 S



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



RN 405142-77-0 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-7-fluoro-9-methyl-4-oxo-8-

[4,5,6,7-tetrahydro-6-methyl-5-(triphenylmethyl)thieno[3,2-c]pyridin-2-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 405142-79-2 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-7-fluoro-9-methyl-4-oxo-8-(4,5,6,7-tetrahydro-6-methylthieno[3,2-c]pyridin-2-yl)-, ethyl ester, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 405142-78-1
CMF C24 H25 F N2 O3 S



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



RN 405142-80-5 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-9-methyl-4-oxo-8-[4,5,6,7-tetrahydro-7-(methoxymethoxy)-5-(triphenylmethyl)thieno[3,2-c]pyridin-2-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 405142-81-6 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-9-methyl-4-oxo-8-[4,5,6,7-tetrahydro-7-(methoxymethoxy)thieno[3,2-c]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 405142-82-7 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-9-methyl-4-oxo-8-[4,5,6,7-tetrahydro-7-(methoxymethoxy)thieno[3,2-c]pyridin-2-yl]-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 405142-81-6
CMF C23 H24 N2 O5 S



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



RN 405142-89-4 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-9-(difluoromethoxy)-4-oxo-
8-[4,5,6,7-tetrahydro-5-(triphenylmethyl)thieno[3,2-c]pyridin-2-yl]-,
ethyl ester (9CI) (CA INDEX NAME)



RN 405142-91-8 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-9-(difluoromethoxy)-4-oxo-
8-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)-, ethyl ester,
mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 405142-90-7
CMF C23 H22 F2 N2 O4 S



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



RN 405143-02-4 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-9-methyl-4-oxo-8-[4,5,6,7-
tetrahydro-7-methoxy-5-(triphenylmethyl)thieno[3,2-c]pyridin-2-yl]-,
ethyl
ester (9CI) (CA INDEX NAME)



RN 405143-05-7 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-9-methyl-4-oxo-8-(4,5,6,7-
tetrahydro-7-methoxythieno[3,2-c]pyridin-2-yl)-, ethyl ester,
mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 405143-04-6
CMF C24 H26 N2 O4 S



RN 405142-95-2 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-9-methyl-4-oxo-8-[4,5,6,7-
tetrahydro-6-[(methoxymethoxy)methyl]-5-(triphenylmethyl)thieno[3,2-
c]pyridin-2-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 405142-96-3 CAPLUS
CN Thieno[3,2-c]pyridine, 4,5,6,7-tetrahydro-6-[(methoxymethoxy)methyl]-2-
(4,4,5,5-tetramethyl-1,3,2-dioxaborinan-2-yl)-5-(triphenylmethyl)- (9CI)
(CA INDEX NAME)



RN 405142-98-5 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-9-methyl-4-oxo-8-[4,5,6,7-
tetrahydro-6-[(methoxymethoxy)methyl]thieno[3,2-c]pyridin-2-yl]-, ethyl
ester, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 405142-97-4
CMF C26 H30 N2 O5 S



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



RN 405143-22-8 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-9-methyl-4-oxo-8-[4,5,6,7-
tetrahydro-5-(triphenylmethyl)-7-[(triphenylmethyl)amino]thieno[3,2-
c]pyridin-2-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 405143-27-3 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid,
1-cyclopropyl-9-methyl-4-oxo-8-[4,5,6,7-

tetrahydro-5-methyl-7-[(triphenylmethyl)amino]thieno[3,2-c]pyridin-2-yl]-,
ethyl ester (9CI) (CA INDEX NAME)

L6 ANSWER 12 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L6 ANSWER 13 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:338526 CAPLUS
DOCUMENT NUMBER: 134:353259
TITLE: Quinoline- and naphthyridinecarboxylic acid antibacterials
INVENTOR(S): Elmore, Steven W.; Cooper, Curt S.; Schultz, Colleen C.; Hutchinson, Douglas K.; Donner, Pamela L.; Green, Brian E.; Anderson, David D.; Xie, Qinghua; Dinges, Jurgen; Lynch, Linda M.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 294 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001032655	A2	20010510	WO 2000-US30551	20001106
WO 2001032655	A3	20020124		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1226146	A2	20020731	EP 2000-976992	20001106
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003524633	T2	20030819	JP 2001-535357	20001106
BR 2000010728	A	20040217	BR 2000-10728	20001106
ZA 2002002187	A	20041117	ZA 2002-2187	20020318
NO 2002002156	A	20020704	NO 2002-2156	20020506
BG 106679	A	20030131	BG 2002-106679	20020509
PRIORITY APPLN. INFO.:			US 1999-435297 A	19991105
			US 2000-705332 A	20001103
			WO 2000-US30551 W	20001106

OTHER SOURCE(S): MARPAT 134:353259
GI

L6 ANSWER 13 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I



II

AB Title compds. I [A1 = N, (un)substituted CH; A2 = S, O, (un)substituted NH; Z = N, (un)substituted CH; R1 = H, halo, (un)substituted NH2; R2 = (un)substituted alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocyclic; R3 = (un)substituted OH; R4R5 = atoms required to complete an (un)substituted carbocycle or heterocycle] were prepared for use as antibacterial agents. Thus, 2-thienylethylamine was methylenated and cyclized to 4,5,6,7-tetrahydrothieno[3,2-c]pyridine which was tritylated in the 5-position, tributylstannylated, and treated with Et 7-bromo-1-cyclopropyl-8-methoxy-4-oxo-1,4-dihydro-3-quinolinecarboxylate, followed by ester hydrolysis to give the title compound II. II had an min.
inhibitor concentration against Staphylococcus aureus ATCC 6538P of 0.05 mg/mL.

IT **339050-56-5P 339050-67-8P 339050-74-7P**
339050-82-7P 339053-35-9P 339053-40-6P
339053-56-4P 339053-93-9P 339054-04-5P
339054-11-4P 339054-19-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinoline- and naphthyridinecarboxylic acid antibacterials)

RN 339050-56-5 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-7-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)-, hydrochloride (9CI) (CA INDEX NAME)

L6 ANSWER 13 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



●x HCl

RN 339050-67-8 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydro-6-methylthieno[3,2-c]pyridin-2-yl)-, hydrobromide (9CI) (CA INDEX NAME)



●x HBr

RN 339050-74-7 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-8-(difluoromethoxy)-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydro-4-methylthieno[3,2-c]pyridin-2-yl)-, hydrobromide (9CI) (CA INDEX NAME)



●x HBr

RN 339050-82-7 CAPLUS

CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-8-(difluoromethoxy)-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydro-7,7-dimethylthieno[3,2-c]pyridin-2-yl)-, hydrobromide (9CI) (CA INDEX NAME)



●x HBr

RN 339053-35-9 CAPLUS

CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-7-(4,5,6,7-tetrahydro-7-hydroxythieno[3,2-c]pyridin-2-yl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 339053-40-6 CAPLUS

CN 3-Quinolinecarboxylic acid, 7-(7-amino-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo- (9CI) (CA INDEX NAME)



RN 339053-56-4 CAPLUS



RN 339054-19-2 CAPLUS

CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-8-(difluoromethoxy)-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydro-7,7-dimethylthieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



IT **339057-00-0 339057-01-1 339057-05-5 339057-15-7 339057-18-0 339057-19-1**

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of quinoline- and naphthyridinecarboxylic acid antibacterials)

RN 339057-00-0 CAPLUS

CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-7-[5-[(1,1-dimethylethoxy)carbonyl]-4,5,6,7-tetrahydro-7-hydroxythieno[3,2-c]pyridin-2-yl]-1,4-dihydro-8-methoxy-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 339057-01-1 CAPLUS

CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-7-[5-[(1,1-dimethylethoxy)carbonyl]-4,5,6,7-tetrahydro-7-oxothieno[3,2-c]pyridin-2-yl]-1,4-dihydro-8-methoxy-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)

CN 3-Quinolinecarboxylic acid, 7-[7-amino-4,5,6,7-tetrahydro-5-(methylsulfonyl)thieno[3,2-c]pyridin-2-yl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo- (9CI) (CA INDEX NAME)



RN 339053-93-9 CAPLUS

CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-7-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 339054-04-5 CAPLUS

CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydro-6-methylthieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 339054-11-4 CAPLUS

CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-8-(difluoromethoxy)-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydro-4-methylthieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 339057-05-5 CAPLUS

CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-7-[5-[(1,1-dimethylethoxy)carbonyl]-7-[[(1,1-dimethylethoxy)carbonyl]amino]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl]-1,4-dihydro-8-methoxy-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 339057-15-7 CAPLUS

CN 3-Quinolinecarboxylic acid, 7-[7-azido-5-[(1,1-dimethylethoxy)carbonyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 339057-18-0 CAPLUS

CN 3-Quinolinecarboxylic acid, 7-[5-acetyl-7-[[(1,1-dimethylethoxy)carbonyl]amino]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo- (9CI) (CA INDEX NAME)



RN 339057-19-1 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-7-[7-[[(1,1-dimethylethoxy)carbonyl]amino]-4,5,6,7-tetrahydro-5-(methylsulfonyl)thieno[3,2-c]pyridin-2-yl]-1,4-dihydro-8-methoxy-4-oxo- (9CI) (CA INDEX NAME)



IT **339054-93-2P 339054-94-3P 339054-95-4P**
339054-97-6P 339054-98-7P 339054-99-8P
339055-00-4P 339055-01-5P 339055-12-8P
339055-13-9P 339055-14-0P 339055-15-1P
339055-16-2P 339055-17-3P 339055-18-4P
339055-19-5P 339055-23-1P 339055-24-2P
339055-25-3P 339055-26-4P 339055-27-5P
339055-38-8P 339055-39-9P 339055-40-2P
339055-41-3P 339055-42-4P 339055-43-5P
339056-36-9P 339056-37-0P 339056-38-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of quinoline- and naphthyridinecarboxylic acid antibacterials)

RN 339054-93-2 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-[4,5,6,7-tetrahydro-5-(triphenylmethyl)thieno[3,2-c]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 339054-94-3 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-7-[4,5,6,7-tetrahydro-5-(triphenylmethyl)thieno[3,2-c]pyridin-2-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 339054-95-4 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-7-[4,5,6,7-tetrahydro-5-(triphenylmethyl)thieno[3,2-c]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 339054-97-6 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-[4,5,6,7-tetrahydro-5-(triphenylmethyl)thieno[3,2-c]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 339054-98-7 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[4,5,6,7-tetrahydro-5-(triphenylmethyl)thieno[3,2-c]pyridin-2-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 339054-99-8 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[4,5,6,7-tetrahydro-5-(triphenylmethyl)thieno[3,2-c]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 339055-00-4 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-8-(difluoromethoxy)-1,4-dihydro-4-oxo-7-[4,5,6,7-tetrahydro-5-(triphenylmethyl)thieno[3,2-c]pyridin-2-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 339055-01-5 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-8-(difluoromethoxy)-1,4-dihydro-4-oxo-7-[4,5,6,7-tetrahydro-5-(triphenylmethyl)thieno[3,2-c]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 339055-12-8 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-[4,5,6,7-tetrahydro-6-methyl-5-[(phenylmethoxy)carbonyl]thieno[3,2-c]pyridin-2-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 339055-13-9 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-[4,5,6,7-tetrahydro-6-methyl-5-[(phenylmethoxy)carbonyl]thieno[3,2-c]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 339055-14-0 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid,
1-cyclopropyl-6-fluoro-1,4-dihydro-4-
oxo-7-[4,5,6,7-tetrahydro-6-methyl-5-[(phenylmethoxy)carbonyl]thieno[3,2-c]pyridin-2-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 339055-15-1 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid,
1-cyclopropyl-6-fluoro-1,4-dihydro-4-
oxo-7-[4,5,6,7-tetrahydro-6-methyl-5-[(phenylmethoxy)carbonyl]thieno[3,2-c]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 339055-16-2 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-[4,5,6,7-tetrahydro-6-methyl-5-[(phenylmethoxy)carbonyl]thieno[3,2-c]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 339055-17-3 CAPLUS
CN 3-Quinolinecarboxylic acid,
1-cyclopropyl-8-(difluoromethoxy)-1,4-dihydro-
4-oxo-7-[4,5,6,7-tetrahydro-6-methyl-5-[(phenylmethoxy)carbonyl]thieno[3,2-c]pyridin-2-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 339055-18-4 CAPLUS
CN 3-Quinolinecarboxylic acid,
1-cyclopropyl-8-(difluoromethoxy)-1,4-dihydro-
4-oxo-7-[4,5,6,7-tetrahydro-6-methyl-5-[(phenylmethoxy)carbonyl]thieno[3,2-c]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 339055-19-5 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-7-[4,5,6,7-tetrahydro-6-methyl-5-[(phenylmethoxy)carbonyl]thieno[3,2-c]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 339055-23-1 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-[4,5,6,7-tetrahydro-4-methyl-5-[(phenylmethoxy)carbonyl]thieno[3,2-c]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 339055-24-2 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-[4,5,6,7-tetrahydro-4-methyl-5-[(phenylmethoxy)carbonyl]thieno[3,2-c]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 339055-25-3 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid,
1-cyclopropyl-6-fluoro-1,4-dihydro-4-
oxo-7-[4,5,6,7-tetrahydro-4-methyl-5-[(phenylmethoxy)carbonyl]thieno[3,2-c]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 339055-26-4 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-7-[4,5,6,7-tetrahydro-4-methyl-5-[(phenylmethoxy)carbonyl]thieno[3,2-c]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 339055-27-5 CAPLUS
CN 3-Quinolinecarboxylic acid,
1-cyclopropyl-8-(difluoromethoxy)-1,4-dihydro-
4-oxo-7-[4,5,6,7-tetrahydro-4-methyl-5-[(phenylmethoxy)carbonyl]thieno[3,2-c]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 339055-38-8 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-[4,5,6,7-tetrahydro-7,7-dimethyl-5-[(phenylmethoxy)carbonyl]thieno[3,2-c]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 339055-39-9 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-[4,5,6,7-tetrahydro-7,7-dimethyl-5-[(phenylmethoxy)carbonyl]thieno[3,2-c]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 339055-40-2 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-7-[4,5,6,7-tetrahydro-7,7-dimethyl-5-[(phenylmethoxy)carbonyl]thieno[3,2-c]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 339055-41-3 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[4,5,6,7-tetrahydro-7,7-dimethyl-5-[(phenylmethoxy)carbonyl]thieno[3,2-c]pyridin-2-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 339056-37-0 CAPLUS
CN 3-Quinolinecarboxylic acid, 7-(5-acetyl-7-azido-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 339056-38-1 CAPLUS
CN 3-Quinolinecarboxylic acid, 7-[7-azido-4,5,6,7-tetrahydro-5-(methylsulfonyl)thieno[3,2-c]pyridin-2-yl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)



IT 339050-55-4P 339050-57-6P 339050-58-7P
339050-59-8P 339050-65-6P 339050-66-7P
339050-68-9P 339050-69-0P 339050-70-3P
339050-71-4P 339050-72-5P 339050-73-6P
339050-78-1P 339050-79-2P 339050-80-5P
339050-81-6P 339053-36-0P 339053-52-0P
339053-55-3P 339053-92-8P 339053-94-0P
339053-95-1P 339053-96-2P 339054-02-3P
339054-03-4P 339054-05-6P 339054-06-7P
339054-07-8P 339054-08-9P 339054-09-0P
339054-10-3P 339054-15-8P 339054-16-9P
339054-17-0P 339054-18-1P 339054-67-0P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological



RN 339055-42-4 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[4,5,6,7-tetrahydro-7,7-dimethyl-5-[(phenylmethoxy)carbonyl]thieno[3,2-c]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 339055-43-5 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-8-(difluoromethoxy)-1,4-dihydro-4-oxo-7-[4,5,6,7-tetrahydro-7,7-dimethyl-5-[(phenylmethoxy)carbonyl]thieno[3,2-c]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 339056-36-9 CAPLUS
CN 3-Quinolinecarboxylic acid, 7-(7-azido-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)

study); PREP (Preparation); USES (Uses)
(prepn. of quinoline- and naphthyridinecarboxylic acid antibacterials)

RN 339050-55-4 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 339050-57-6 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 339050-58-7 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 339050-59-8 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-8-(difluoromethoxy)-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 339050-65-6 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydro-6-methylthieno[3,2-c]pyridin-2-yl)-, hydrobromide (9CI) (CA INDEX NAME)



●x HBr

RN 339050-66-7 CAPLUS



●x HBr

RN 339050-70-3 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydro-4-methylthieno[3,2-c]pyridin-2-yl)-, hydrobromide (9CI) (CA INDEX NAME)



●x HBr

RN 339050-71-4 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydro-4-methylthieno[3,2-c]pyridin-2-yl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 339050-72-5 CAPLUS

CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydro-6-methylthieno[3,2-c]pyridin-2-yl)-, hydrobromide (9CI) (CA INDEX NAME)



●x HBr

RN 339050-68-9 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-8-(difluoromethoxy)-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydro-6-methylthieno[3,2-c]pyridin-2-yl)-, hydrobromide (9CI) (CA INDEX NAME)



●x HBr

RN 339050-69-0 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-7-(4,5,6,7-tetrahydro-6-methylthieno[3,2-c]pyridin-2-yl)-, hydrobromide (9CI) (CA INDEX NAME)

CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydro-4-methylthieno[3,2-c]pyridin-2-yl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 339050-73-6 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-7-(4,5,6,7-tetrahydro-4-methylthieno[3,2-c]pyridin-2-yl)-, hydrobromide (9CI) (CA INDEX NAME)



●x HBr

RN 339050-78-1 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydro-7,7-dimethylthieno[3,2-c]pyridin-2-yl)-, hydrobromide (9CI) (CA INDEX NAME)



●x HBr

RN 339050-79-2 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydro-7,7-dimethylthieno[3,2-c]pyridin-2-yl)-, hydrobromide (9CI) (CA INDEX NAME)



●x HBr

RN 339050-80-5 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-7-(4,5,6,7-tetrahydro-7,7-dimethylthieno[3,2-c]pyridin-2-yl)-, hydrobromide (9CI) (CA INDEX NAME)



●x HBr

RN 339050-81-6 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-

oxo-7-(4,5,6,7-tetrahydro-7,7-dimethylthieno[3,2-c]pyridin-2-yl)-, hydrobromide (9CI) (CA INDEX NAME)



●x HBr

RN 339053-36-0 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-7-(4,5,6,7-tetrahydro-7-oxothieno[3,2-c]pyridin-2-yl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 339053-52-0 CAPLUS
CN 3-Quinolinecarboxylic acid, 7-(7-azido-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo- (9CI) (CA INDEX NAME)



RN 339053-55-3 CAPLUS
CN 3-Quinolinecarboxylic acid, 7-(5-acetyl-7-amino-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)-1-cyclopropyl-1,4-dihydro-8-methoxy-4-

oxo- (9CI) (CA INDEX NAME)



RN 339053-92-8 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 339053-94-0 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 339053-95-1 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 339053-96-2 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-8-(difluoromethoxy)-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 339054-02-3 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydro-6-methylthieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 339054-03-4 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydro-6-methylthieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 339054-05-6 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-8-(difluoromethoxy)-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydro-6-methylthieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 339054-06-7 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-7-(4,5,6,7-tetrahydro-6-methylthieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 339054-07-8 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydro-4-methylthieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 339054-08-9 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydro-4-methylthieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 339054-09-0 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydro-4-methylthieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 339054-10-3 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-7-(4,5,6,7-tetrahydro-4-methylthieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 339054-15-8 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydro-7,7-dimethylthieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 339054-16-9 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydro-7,7-dimethylthieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 339054-17-0 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-7-(4,5,6,7-tetrahydro-7,7-dimethylthieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 339054-18-1 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4,5,6,7-tetrahydro-7,7-dimethylthieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 339054-67-0 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-7-(4,5,6,7-tetrahydro-7-oxothieno[3,2-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



L6 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:457050 CAPLUS
DOCUMENT NUMBER: 133:79374
TITLE: Aromatic heterocyclic compounds as thrombin or factor Xa inhibitors
INVENTOR(S): Lam, Patrick Yuk Sun; Clark, Charles G.; Li, Hui Yin; Pinto, Donald J. P.
PATENT ASSIGNEE(S): Du Pont Pharmaceuticals Co., USA
SOURCE: PCT Int. Appl., 121 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000039108	A1	20000706	WO 1999-US30512	19991222
W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2349557	AA	20000706	CA 1999-2349557	19991222
EP 1140871	A1	20011010	EP 1999-967485	19991222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6369227	B1	20020409	US 1999-469830	19991222
US 6403583	B1	20020611	US 1999-469835	19991222
JP 2002537227	T2	20021105	JP 2000-591019	19991222
US 2002115854	A1	20020822	US 2001-7195	20011204
US 6602871	B2	20030805		
US 6500855	B1	20021231	US 2002-33137	20020102
US 2003004344	A1	20030102		

PRIORITY APPLN. INFO.: US 1998-113627P P 19981223
US 1999-469830 A3 19991222
US 1999-469831 B1 19991222
WO 1999-US30512 W 19991222

OTHER SOURCE(S): MARPAT 133:79374
AB This invention relates generally to inhibitors of trypsin-like serine protease enzymes, especially factor Xa or thrombin, pharmaceutical compns.
containing the same, and methods of using the same as anticoagulant agents for
treatment and prevention of thromboembolic disorders.
IT **280130-06-5D**, derivs. **280130-10-1D**, derivs.
280130-24-7D, derivs. **280130-28-1D**, derivs.
280130-43-0D, derivs. **280130-47-4D**, derivs.
280130-61-2D, derivs. **280130-65-6D**, derivs.
280130-79-2D, derivs. **280130-83-8D**, derivs.
280130-97-4D, derivs. **280131-01-3D**, derivs.
280131-15-9D, derivs. **280131-19-3D**, derivs.
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)

L6 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(arom. heterocyclic compds. as thrombin or factor Xa inhibitors)

RN 280130-06-5 CAPLUS
CN Thieno[3,2-c]pyridin-4-amine, 3-(1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)



RN 280130-10-1 CAPLUS
CN Thieno[3,2-c]pyridin-4-amine, 2-(1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)



RN 280130-24-7 CAPLUS
CN Thieno[3,2-c]pyridin-4-amine, 3-(1H-1,2,3-triazol-1-yl)- (9CI) (CA INDEX NAME)



RN 280130-28-1 CAPLUS
CN Thieno[3,2-c]pyridin-4-amine, 2-(1H-1,2,3-triazol-1-yl)- (9CI) (CA INDEX NAME)



RN 280130-43-0 CAPLUS
CN Thieno[3,2-c]pyridin-4-amine, 3-(4-oxazolyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 280130-47-4 CAPLUS
CN Thieno[3,2-c]pyridin-4-amine, 2-(4-oxazolyl)- (9CI) (CA INDEX NAME)



RN 280130-61-2 CAPLUS
CN Thieno[3,2-c]pyridin-4-amine, 3-(4-thiazolyl)- (9CI) (CA INDEX NAME)



RN 280130-65-6 CAPLUS
CN Thieno[3,2-c]pyridin-4-amine, 2-(4-thiazolyl)- (9CI) (CA INDEX NAME)



RN 280130-79-2 CAPLUS
CN Thieno[3,2-c]pyridin-4-amine, 3-(1H-imidazol-4-yl)- (9CI) (CA INDEX NAME)



RN 280130-83-8 CAPLUS
CN Thieno[3,2-c]pyridin-4-amine, 2-(1H-imidazol-4-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 280130-97-4 CAPLUS
CN Thieno[3,2-c]pyridin-4-amine, 3-(3-isoxazolyl)- (9CI) (CA INDEX NAME)



RN 280131-01-3 CAPLUS
CN Thieno[3,2-c]pyridin-4-amine, 2-(3-isoxazolyl)- (9CI) (CA INDEX NAME)



RN 280131-15-9 CAPLUS
CN Thieno[3,2-c]pyridin-4-amine, 3-(1H-tetrazol-1-yl)- (9CI) (CA INDEX NAME)



RN 280131-19-3 CAPLUS
CN Thieno[3,2-c]pyridin-4-amine, 2-(1H-tetrazol-1-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L6 ANSWER 15 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:113686 CAPLUS
DOCUMENT NUMBER: 130:182449
TITLE: Hydroxamic acid substituted fused heterocyclic metalloproteinase inhibitors
INVENTOR(S): Thomson, David S.; Koch, Kevin; Hwang, Chan Kou; Russo-Rodriguez, Sandra E.; Hummel, Conrad
PATENT ASSIGNEE(S): Amgen Inc., USA
SOURCE: PCT Int. Appl., 428 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9906410	A1	19990211	WO 1998-US16147	19980804
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2297988	AA	19990211	CA 1998-2297988	19980804
AU 9887664	A1	19990222	AU 1998-87664	19980804
EP 1003751	A1	20000531	EP 1998-939182	19980804
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2003524572	T2	20030819	JP 2000-505168	19980804
PRIORITY APPLN. INFO.:			US 1997-54753P	P 19970804
			US 1998-128512	A 19980803
			WO 1998-US16147	W 19980804

OTHER SOURCE(S): MARPAT 130:182449
GI



I



II

AB Hydroxamic acid substituted fused heterocyclic compds. I [R1 = (un)substituted aliphatic cycloalkyl, heterocyclic; R2 = H, alkyl; V = (un)substituted CH2, CH2CH2; WN = CON, (un)substituted COCH2N, CH2N, CH2CH2N; X = O, S, Y = (un)substituted CH, Z = N, (un)substituted CH; Y = O, S, X, Z = (un)substituted CH; Z = O, S, X = N, (un)substituted CH, Y = (un)substituted CH] are effective for prophylaxis and treatment of inflammation, tissue degradation and related diseases. Thus, 2-thiophenecarboxaldehdye was treated with glycine and cyclized with CH2O to give the thienopyridine II [R3 = OH, R4 = H] which was 4-methoxybenzenesulfonylated, O-acetylated, treated with NH2OH, and

L6 ANSWER 15 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

deacetylated to give II [R3 = NHOH, R4 = SO2C6H4OMe-4]. I are inhibitors of tumor necrosis factor convertase, human neutrophil collagenase, and human fibroblast stromelysin.

IT **220564-63-6P 220564-64-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thia- and oxaazabicycloalkanecarbohydroxamic acids as metalloproteinase inhibitors)

RN 220564-63-6 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide, 4,5,6,7-tetrahydro-N,7-dihydroxy-5-[(4-methoxyphenyl)sulfonyl]-2-(2-pyridinyl)-, (6R,7R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 220564-64-7 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide, 4,5,6,7-tetrahydro-N,7-dihydroxy-5-[(4-methoxyphenyl)sulfonyl]-2-(3-pyridinyl)-, (6R,7R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **220566-04-1P 220566-05-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of thia- and oxaazabicycloalkanecarbohydroxamic acids as metalloproteinase inhibitors)

RN 220566-04-1 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide, N-(diphenylmethoxy)-4,5,6,7-tetrahydro-5-[(4-methoxyphenyl)sulfonyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 220566-05-2 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide, N-(diphenylmethoxy)-4,5,6,7-tetrahydro-5-[(4-methoxyphenyl)sulfonyl]-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)



IT **220564-86-3P 220564-87-4P 220567-42-0P 220567-44-2P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thia- and oxaazabicycloalkanecarbohydroxamic acids as metalloproteinase inhibitors)

RN 220564-86-3 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide, 4,5,6,7-tetrahydro-N-hydroxy-5-[(4-methoxyphenyl)sulfonyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 220564-87-4 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide, 4,5,6,7-tetrahydro-N-hydroxy-5-[(4-methoxyphenyl)sulfonyl]-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 220567-42-0 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide, 4,5,6,7-tetrahydro-N,7-dihydroxy-5-[(4-methoxyphenyl)sulfonyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 220567-44-2 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxamide, 4,5,6,7-tetrahydro-N,7-dihydroxy-5-

[(4-methoxyphenyl)sulfonyl]-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

ACCESSION NUMBER: 1995:537252 CAPLUS
DOCUMENT NUMBER: 123:111894
TITLE: A facile synthesis of 3-hydroxythieno[3,2-c]quinolin-4(5H)-ones
AUTHOR(S): Gupta, M. C. L. N.; Darbarwar, Malleshwar
CORPORATE SOURCE: Dep. Chem., Osmania Univ., Hyderabad, 500 007, India
SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1995), 34B(5), 432-5
CODEN: IJSBDB; ISSN: 0376-4699
PUBLISHER: Publications & Information Directorate, CSIR
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



II

AB Reaction of 4-chloroquinolin-2(1H)-ones with 2-mercaptoacetic and -propionic acid in the presence of base furnishes 2-[(1,2-dihydro-2-oxo-4-quinolinyl)thio]acetic and -propionic acids, which, on cyclodehydration in polyphosphoric acid, afford the title compds. (I; R1 = Me, Et, Ph; R2 = H, Me). Aldol-type condensation products (II) are formed from I on standing in aqueous acid medium.

IT **166191-84-0P 166191-85-1P 166191-86-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of hydroxythienoquinolinones)

RN 166191-84-0 CAPLUS
CN [2,3'-Bithieno[3,2-c]quinoline]-4,4'(5H,5'H)-dione, 3-hydroxy-5,5'-dimethyl- (9CI) (CA INDEX NAME)



RN 166191-85-1 CAPLUS
CN [2,3'-Bithieno[3,2-c]quinoline]-4,4'(5H,5'H)-dione, 5,5'-diethyl-3-hydroxy- (9CI) (CA INDEX NAME)



RN 166191-86-2 CAPLUS
CN [2,3'-Bithieno[3,2-c]quinoline]-4,4'(5H,5'H)-dione, 3-hydroxy-5,5'-diphenyl- (9CI) (CA INDEX NAME)



L6 ANSWER 17 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1994:621033 CAPLUS
DOCUMENT NUMBER: 121:221033
TITLE: Comparative QSAR studies of two series of 1,4-dihydropyridines as slow calcium channel blockers
AUTHOR(S): Wikel, J. H.; Bemis, K. G.; Kurz, Ken; Denney, M. L.; Main, Bradley W.; Moore, R. A.; Smith, Tommy; Shingleton, Larry; Holland, D. R.
CORPORATE SOURCE: Lilly Res. Lab., Eli Lilly and Co., Indianapolis, IN, 46285, USA
SOURCE: Drug Design and Discovery (1994), 11(1), 1-14
CODEN: DDDIEV; ISSN: 1055-9612
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Quant. structure activity anal. was applied to 2 series of dihydropyridine (DHP) calcium channel blocking agents. One series of compds. was composed of DHPs substituted in the 4-position with an ortho or meta nitro substituted Ph ring. The second group consisted of DHPs substituted at the 4-position with a novel thieno[3,2-c]pyridine ring. Both series consisted of compds. with unsym. ester substitutions on the dihydropyridine ring. The antihypertensive activity of the compds. was determined in a spontaneously hypertensive rat model. Regression anal. indicated the antihypertensive activity of an i.v. dose correlated with the calculated octanol/water coefficient (clogP). Regression anal. did not find a correlation with the in vitro potency and the clogP values.

IT **109771-44-0P**, LY 195336 **109771-45-1P**, LY 213151
109771-49-5P, LY 175918 **109771-82-6P**, LY 201416
109771-87-1P, LY 190432 **158314-15-9P**, LYS 281020
158314-16-0P, LY 227233 **158314-17-1P**, LY 237513
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and comparative QSAR study of dihydropyridine slow calcium channel blockers)

RN 109771-44-0 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-thieno[3,2-c]pyridin-3-yl-, methyl 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 109771-45-1 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-thieno[3,2-c]pyridin-3-yl-, methyl 1-methylpropyl ester (9CI) (CA INDEX NAME)

L6 ANSWER 17 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 109771-49-5 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-thieno[3,2-c]pyridin-3-yl-, diethyl ester (9CI) (CA INDEX NAME)



RN 109771-82-6 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-thieno[3,2-c]pyridin-3-yl-, 1,1-dimethylethyl methyl ester (9CI) (CA INDEX NAME)



RN 109771-87-1 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-thieno[3,2-c]pyridin-3-yl-, cyclopropylmethyl methyl ester (9CI) (CA INDEX NAME)

L6 ANSWER 17 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 158314-15-9 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-thieno[3,2-c]pyridin-3-yl-, methyl 2-propynyl ester (9CI) (CA INDEX NAME)



RN 158314-16-0 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-thieno[3,2-c]pyridin-3-yl-, cyclobutylmethyl methyl ester (9CI) (CA INDEX NAME)



RN 158314-17-1 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-thieno[3,2-c]pyridin-3-yl-, 2,2-dimethylpropyl methyl ester (9CI) (CA INDEX NAME)

L6 ANSWER 17 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L6 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1990:434706 CAPLUS
DOCUMENT NUMBER: 113:34706
TITLE: 4-[Thieno[3,2-c]pyridinyl]pyridinecarboxylic acid esters as calcium channel modulators
INVENTOR(S): Holland, Donald R.; Wikel, James H.
PATENT ASSIGNEE(S): Eli Lilly and Co., USA
SOURCE: U.S., 7 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4902694	A	19900220	US 1988-231310	19880811
PRIORITY APPLN. INFO.:			US 1988-231310	19880811

OTHER SOURCE(S): MARPAT 113:34706
GI



I

AB The title compds. [I; R = cyanoethyl, (un)substituted C1-6 aliphatic radical] modulate Ca flux across Ca channels and are useful for the treatment of cardiovascular diseases, such as congestive heart failure. Thirty compds. were prepared and clin. effects of the compds. on the cardiovascular system were tested with beagle dogs. A suspension contained I (R = 2-propynyl) 5 mg, Na CM-cellulose 50 mg, syrup 1.25 mL, benzoic acid solution 0.10 mL, flavor and color q.s., and water to 5 mL.

IT 123250-77-1P 128133-02-8P 128133-03-9P
128133-04-0P 128133-05-1P 128133-06-2P
128133-07-3P 128133-08-4P 128133-09-5P
128133-10-8P 128133-11-9P 128133-12-0P
128133-13-1P 128133-14-2P 128133-15-3P
128133-16-4P 128133-17-5P 128133-18-6P
128133-19-7P 128133-20-0P 128133-21-1P
128133-22-2P 128133-23-3P 128133-24-4P
128133-25-5P 128133-26-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as calcium channel modulator)

RN 123250-77-1 CAPLUS
CN 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-thieno[3,2-c]pyridin-3-yl-, 1-phenylethyl ester (9CI) (CA INDEX NAME)

L6 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 128133-02-8 CAPLUS
CN 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-thieno[3,2-c]pyridin-3-yl-, butyl ester (9CI) (CA INDEX NAME)



RN 128133-03-9 CAPLUS
CN 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-thieno[3,2-c]pyridin-3-yl-, 1-methylpropyl ester (9CI) (CA INDEX NAME)



RN 128133-04-0 CAPLUS
CN 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-thieno[3,2-c]pyridin-3-yl-, methyl ester (9CI) (CA INDEX NAME)

L6 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 128133-05-1 CAPLUS
CN 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-thieno[3,2-c]pyridin-3-yl-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 128133-06-2 CAPLUS
CN 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-thieno[3,2-c]pyridin-3-yl-, 2-propynyl ester (9CI) (CA INDEX NAME)



RN 128133-07-3 CAPLUS
CN 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-thieno[3,2-c]pyridin-3-yl-, 1-methyl-2-propynyl ester (9CI) (CA INDEX NAME)

L6 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 128133-08-4 CAPLUS
CN 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-thieno[3,2-c]pyridin-3-yl-, 2-butynyl ester (9CI) (CA INDEX NAME)



RN 128133-09-5 CAPLUS
CN 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-thieno[3,2-c]pyridin-3-yl-, 1-methyl-2-butynyl ester (9CI) (CA INDEX NAME)



RN 128133-10-8 CAPLUS
CN 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-thieno[3,2-c]pyridin-3-yl-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)



RN 128133-11-9 CAPLUS
CN 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-thieno[3,2-c]pyridin-3-yl-, 3-butynyl ester (9CI) (CA INDEX NAME)



RN 128133-12-0 CAPLUS
CN 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-thieno[3,2-c]pyridin-3-yl-, 1,1-dimethyl-2-propynyl ester (9CI) (CA INDEX NAME)



RN 128133-13-1 CAPLUS
CN 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-thieno[3,2-c]pyridin-3-yl-, 1,2,2-trimethylpropyl ester (9CI) (CA INDEX NAME)



RN 128133-14-2 CAPLUS
CN 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-thieno[3,2-c]pyridin-3-yl-, 2-methyl-1-phenylpropyl ester (9CI) (CA INDEX NAME)



RN 128133-15-3 CAPLUS
CN 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-thieno[3,2-c]pyridin-3-yl-, 1-methyl-1-phenylethyl ester (9CI) (CA INDEX NAME)



RN 128133-16-4 CAPLUS
CN 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-thieno[3,2-c]pyridin-3-yl-, 1-phenylpropyl ester (9CI) (CA INDEX NAME)



RN 128133-17-5 CAPLUS
CN 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-thieno[3,2-c]pyridin-3-yl-, (4-methoxyphenyl)methyl ester (9CI) (CA INDEX NAME)



RN 128133-18-6 CAPLUS
CN 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-thieno[3,2-c]pyridin-3-yl-, 1-methyl-2-phenylethyl ester (9CI) (CA INDEX NAME)



RN 128133-19-7 CAPLUS
CN 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-thieno[3,2-c]pyridin-3-yl-, 2-phenylpropyl ester (9CI) (CA INDEX NAME)



RN 128133-20-0 CAPLUS
CN 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-thieno[3,2-c]pyridin-3-yl-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 128133-21-1 CAPLUS
CN 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-thieno[3,2-c]pyridin-3-yl-, 2-phenoxyethyl ester (9CI) (CA INDEX NAME)



RN 128133-22-2 CAPLUS
CN 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-thieno[3,2-c]pyridin-3-yl-, 3-phenyl-2-propynyl ester (9CI) (CA INDEX NAME)



RN 128133-23-3 CAPLUS
CN 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-thieno[3,2-c]pyridin-3-yl-, 2-methoxy-2-phenylethyl ester (9CI) (CA INDEX NAME)



RN 128133-24-4 CAPLUS
CN 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-thieno[3,2-c]pyridin-3-yl-, cyclopropylmethyl ester (9CI) (CA INDEX NAME)



RN 128133-25-5 CAPLUS
CN 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-thieno[3,2-c]pyridin-3-yl-, 1-cyclopropylethyl ester (9CI) (CA INDEX NAME)



RN 128133-26-6 CAPLUS
CN 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-thieno[3,2-c]pyridin-3-yl-, 2-cyanoethyl ester (9CI) (CA INDEX NAME)



ACCESSION NUMBER: 1989:566790 CAPLUS
DOCUMENT NUMBER: 111:166790
TITLE: LY249933: a cardioselective 1,4-dihydropyridine with positive inotropic activity
AUTHOR(S): Holland, Donald R.; Wikel, James H.; Kauffman, Raymond F.; Smallwood, Jeffrey K.; Zimmerman, Karen M.; Utterback, Barbara G.; Turk, John A.; Steinberg, Mitchell I.
CORPORATE SOURCE: Lilly Res. Lab., Eli Lilly and Co., Indianapolis, IN, 46285, USA
SOURCE: Journal of Cardiovascular Pharmacology (1989), 14(3), 483-91
CODEN: JCPCDT; ISSN: 0160-2446
DOCUMENT TYPE: Journal
LANGUAGE: English

AB LY249933 and its component diastereomers, (R,R) and (S,R), were studied for their vascular and cardiac effects in vitro and in vivo. In guinea pig cardiac ventricular membranes, LY249933, (R,R), and (S,R) potently displaced bound [3H]nitrendipine (Kd values = 2-6 nM). In isolated guinea pig right ventricular strips, LY249933 produced a small increase in contraction, whereas (R,R) substantially increased (-log EC50 (M) = 4.6) and (S,R) decreased contraction (-log EC50 (M) = 4.1). In isolated canine cephalic vein, contracted with 80 mM KCl, an increase in contraction was produced by (R,R), whereas relaxation was produced by LY249933 (-log EC50 (M) = 5.9) and (S,R) (-log EC50 (M) = 6.0). At 20 mM KCl, (R,R) increased, (S,R) decreased, but LY249933 did not alter contraction. In anesthetized dogs, LY249933 (200 μg/kg/min, i.v.) increased dP/dt60, decreased heart rate, but did not change vascular resistance or the rate pressure product. At the same dose, (R,R) and (S,R) both tended to increase dP/dt60 nonsignificantly, whereas (R,R) increased and (S,R) decreased vascular resistance. Both (R,R) and (S,R) tended to decrease heart rate nonsignificantly, whereas (R,R) did not change and (S,R) decreased the rate pressure product. Thus, LY249933 produced potentially beneficial cardiovascular changes resulting from the combined actions of its (R,R) and (S,R) diastereomers that are postulated to be a Ca2+ agonist and antagonist, resp.

IT **123250-77-1**, LY 249933 **123250-78-2 123250-79-3**
RL: BIOL (Biological study)
(heart inotropy from, diastereomerism in relation to)

RN 123250-77-1 CAPLUS
CN 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-thieno[3,2-c]pyridin-3-yl-, 1-phenylethyl ester (9CI) (CA INDEX NAME)



RN 123250-78-2 CAPLUS
CN 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-thieno[3,2-c]pyridin-3-yl-, 1-phenylethyl ester, [R-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 123250-79-3 CAPLUS
CN 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-thieno[3,2-c]pyridin-3-yl-, 1-phenylethyl ester, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1987:515496 CAPLUS
DOCUMENT NUMBER: 107:115496
TITLE: Preparation of dihydropyridine derivatives as vasodilators
PATENT ASSIGNEE(S): Eli Lilly and Co., USA
SOURCE: Jpn. Kokai Tokkyo Koho, 21 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 62045586	A2	19870227	JP 1986-196484	19860820
US 4659717	A	19870421	US 1985-768071	19850821
ZA 8606222	A	19880427	ZA 1986-6222	19860818
CA 1265795	A1	19900213	CA 1986-516145	19860818
DK 8603934	A	19870222	DK 1986-3934	19860819
AU 8661584	A1	19870226	AU 1986-61584	19860819
HU 44538	A2	19880328	HU 1986-3635	19860819
HU 195653	B	19880628		
CN 86106294	A	19870225	CN 1986-106294	19860820
EP 217530	A1	19870408	EP 1986-306453	19860820
EP 217530	B1	19901031		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
ES 2001105	A6	19880416	ES 1986-1218	19860820
AT 57930	E	19901115	AT 1986-306453	19860820

PRIORITY APPLN. INFO.: US 1985-768071 A 19850821
EP 1986-306453 A 19860820

OTHER SOURCE(S): MARPAT 107:115496
GI



I II

AB The title compds. (I; R1 = H, C1-4 alkyl, aralkyl; R2 = H, Me, NH2; R3 = H, acyl, alkoxycarbonyl, allylsulfinyl, etc.; R4 = Me, MeO, halo, NO2 NH2; R5 = H, MeO, Me, etc.; A1-A4 = CH, or 1 of them is N; Z = O, S, NH), useful as vasodilators, are prepared Refluxing a mixture of 3.28 g benzo[b]thiophene-2-carboxaldehyde with 5.2 mL MeCOCH2CO2Et and 2 mL NH4OH in EtOH gave 2.62 g benzothienylpyridinedicarboxylate II, which showed -log IC50 of 3.96 in dog's coronary artery in vitro. A capsule formulation contd. I (R1 = R4 = R5 = H, R2 = Me, R3 = CO2Et, A1 = A2 = A4 = CH, A3 = N, Z = S, linkage at A4-position) 250, starch 200, and Mg stearate 10 mg.

IT 109771-44-0P 109771-45-1P 109771-46-2P
109771-49-5P 109771-50-8P 109771-51-9P
109771-52-0P 109771-53-1P 109771-54-2P
109771-60-0P 109771-61-1P 109771-62-2P
109771-70-2P 109771-71-3P 109771-74-6P
109771-79-1P 109771-80-4P 109771-82-6P
109771-84-8P 109771-85-9P 109771-86-0P
109771-87-1P 109789-67-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as vasodilator)

L6 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 109771-44-0 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-thieno[3,2-c]pyridin-3-yl-, methyl 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 109771-45-1 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-thieno[3,2-c]pyridin-3-yl-, methyl 1-methylpropyl ester (9CI) (CA INDEX NAME)



RN 109771-46-2 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-thieno[3,2-c]pyridin-3-yl-, ethyl methyl ester (9CI) (CA INDEX NAME)

L6 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 109771-49-5 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-thieno[3,2-c]pyridin-3-yl-, diethyl ester (9CI) (CA INDEX NAME)



RN 109771-50-8 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-methylthieno[3,2-c]pyridin-3-yl)-, diethyl ester (9CI) (CA INDEX NAME)



RN 109771-51-9 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-thieno[3,2-c]pyridin-3-yl-, bis(1-methylethyl) ester (9CI) (CA INDEX NAME)

L6 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 109771-52-0 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-thieno[3,2-c]pyridin-3-yl-, bis(2-methoxyethyl) ester (9CI) (CA INDEX NAME)



RN 109771-53-1 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-thieno[3,2-c]pyridin-3-yl-, dimethyl ester (9CI) (CA INDEX NAME)



RN 109771-54-2 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-thieno[3,2-c]pyridin-3-yl-, dipropyl ester (9CI) (CA INDEX NAME)



RN 109771-60-0 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-thieno[3,2-c]pyridin-3-yl-, ethyl 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 109771-61-1 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-thieno[3,2-c]pyridin-3-yl-, ethyl 2-methoxyethyl ester (9CI) (CA INDEX NAME)



RN 109771-62-2 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-thieno[3,2-c]pyridin-3-yl-, 2-methoxyethyl methyl ester (9CI) (CA INDEX NAME)



RN 109771-79-1 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-thieno[3,2-c]pyridin-3-yl-, methyl 1-methylpropyl ester, (R)- (9CI) (CA INDEX NAME)



RN 109771-80-4 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-thieno[3,2-c]pyridin-3-yl-, methyl 2-methylpropyl ester (9CI) (CA INDEX NAME)



RN 109771-82-6 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-thieno[3,2-c]pyridin-3-yl-, 1,1-dimethylethyl methyl ester (9CI) (CA INDEX NAME)



RN 109771-70-2 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-thieno[3,2-c]pyridin-3-yl-, methyl 2-[methyl(phenylmethyl)amino]ethyl ester (9CI) (CA INDEX NAME)



RN 109771-71-3 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-thieno[3,2-c]pyridin-3-yl-, 2-cyanoethyl methyl ester (9CI) (CA INDEX NAME)



RN 109771-74-6 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-thieno[3,2-c]pyridin-3-yl-, 2-methoxyethyl 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 109771-84-8 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-thieno[3,2-c]pyridin-3-yl-, methyl 1-phenylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 109771-85-9 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-thieno[3,2-c]pyridin-3-yl-, methyl 2-methylbutyl ester (9CI) (CA INDEX NAME)



RN 109771-86-0 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-thieno[3,2-c]pyridin-3-yl-, methyl 2-propenyl ester (9CI) (CA INDEX NAME)

L6 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 109771-87-1 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-thieno[3,2-c]pyridin-3-yl-, cyclopropylmethyl methyl ester (9CI) (CA INDEX NAME)



RN 109789-67-5 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-thieno[3,2-c]pyridin-2-yl-, diethyl ester (9CI) (CA INDEX NAME)



L6 ANSWER 21 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1984:530610 CAPLUS
DOCUMENT NUMBER: 101:130610
TITLE: Syntheses of 2-alkyl-3-(4-dialkylaminoalkoxybenzoyl)thieno[3,2-c]pyridines
AUTHOR(S): Frehel, Daniel; Boigegrain, Robert; Maffrand, Jean Pierre
CORPORATE SOURCE: Sanofi-Recherche, Toulouse, 31036, Fr.
SOURCE: Heterocycles (1984), 22(5), 1235-47
CODEN: HTCYAM; ISSN: 0385-5414
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 101:130610
GI



AB Thienopyridine isosteres I [R = (CH2)nNR22; R1 = H, Br; R2 = Et, n = 2; R2 = Me, Bu, n = 3] of amiodarone and butoprozin and their tetrahydrogenated analogs II (R3 = COC6H4CH2CH2NR22-4, R4 = Et) were prepared Thus, ticlopidine (II, R3 = R4 = H) was lithiated, treated with MeCHO, and reduced to give thienopyridine II (R3 = H, R4 = Et)(III). Friedel-Crafts acylation III with 4-MeOC6H4COCl gave II (R3 = COC6H4OMe-4, R4 = Et, IV). IV was pyrolyzed to give I (R = Me, R1 = H) which was demethylated and brominated to give I (R = H, R1 = Br). The latter compound was alkylated with Cl(CH2)2NEt2 (V) to give I (R = CH2CH2NEt2, R1 = Br). Demethylation of IV and alkylation with V gave II (R3 = COC6H4CH2CH2NEt2-4, R4 = Et).
IT 90997-36-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 90997-36-7 CAPLUS
CN 1H-Cyclopenta[4,5]thieno[3,2-c]pyridine, 2-[(2-chlorophenyl)methyl]-8-[5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl]-6-ethylidene-2,3,4,6-tetrahydro-7-methyl- (9CI) (CA INDEX NAME)



L6 ANSWER 22 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1928:3433 CAPLUS
DOCUMENT NUMBER: 22:3433
ORIGINAL REFERENCE NO.: 22:420d-i,421a
TITLE: A new thiopyrindigo and a pyrindoxyl
AUTHOR(S): Koenigs, Ernst; Kantrowitz, Herbert
SOURCE: Ber. (1927), 60B, 2097-105
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
AB cf. Plazek and Sucharda, C. A. 21, 407. 4-Mercaptolutidine-3-carboxylic acid (I) was converted with ClCH2CO2H into lutidine-4-[thioglycolic]-3-carboxylic acid (II), which with boiling Ac2O gave 4,6-dimethyl-3-hydroxy-γ,β-pyridothiophene (III), a quite weak base in which the thiophene ring is but little stable (energetic boiling with HCl ruptures it) but which is not so unstable as the 3-hydroxy-α,β-pyridothiophene (IV) (C. A. 19, 1278). All attempts to oxidize the III to the corresponding indigo met with failure at first. Long treatment in alkaline solution with air gave a very faint turbidity soluble in HCl with red-yellow color; addition of Pt sponge improved the yield somewhat but only when air was passed through the hot alkaline solution in the presence of Pt sponge were somewhat practicable results obtained. The isolation of the 4,6,4',6'-tetramethyl-γ,β-thiopyrindigo (V) was also not simple; it was finally effected by extracting the black sludge resulting from the oxidation with PhCl. The V resembles P. and S.'s δ-thiopyrindigo but is not so unstable; it is a weak base and although a HCl salt was obtained with concentrated HCl it partly loses its HCl on drying in a desiccator. The solubility of the V in HCl is too small to permit of its use as basic dye. It smoothly forms a vat in alkaline Na2S2O4 but the leuco compound is apparently difficultly soluble in alkali; the solution is turbid. It dyes cotton very weakly and the intensity of the color is furthermore much reduced in boiling soap, the final shade being a dull pink. After the appearance of P. and S.'s paper, K. and K. also tried to prepare their V directly from the II by heating with H2SO4 and obtained it in this way much more easily than by the method above. On the other hand, they were no more successful than before in obtaining an indigo from IV or α-pyridylthioglycolic acid. N-Lutidyl-4-glycine-3-carboxylic anhydride (VI), from Et γ-chlorolutidine-β-carboxylate and H2NCH2CN, and the corresponding di-CO2H acid (VII) are smoothly converted by boiling Ac2O into 4,6-dimethyl-γ,β-pyrindoxyl (VIII), which is less stable than III and which it has thus far not been possible to oxidize to the pyrindigo. I, m. 235°, easily soluble in alkalies and concentrated mineral acids, is obtained in 43 g. yield from 100 g. Et chlorolutidinecarboxylate first saponified by heating 12 hrs. at 130° with 35 g. KOH in 200 cc. of 70% alc., then concentrated about 0.5, and heated 24 hrs. at 160-70° with 70 g. KSH in H2O; 5 g. yields 5.5 g. II, crystals with 1H2O, m. 247°, easily soluble in alkalies, moderately in concentrated mineral acids; HCl salt, m. 221°. III (1 g. from 2 g. II), red-yellow, m. 49°, easily soluble in acids with yellow to yellow-red, in alkalies only on heating with deep red color; it cannot be recovered from alkalies with acids. HCl salt, bright red, m. 94°. Chloroplatinate, crimson decomps. above 300°. Semicarbazone, pink, decomps. above 300°. p-Diazotoluene coupling product, C16H15ON3S, dark brown, m. 98°, dyes wool and mordanted cotton in dil. HCl a red-brown. V (yield from III, 35%), orange-red prisms with a red metallic streak, sublimes 360° under 15 mm., easily sol. in 2 N HCl; HCl salt, somewhat lighter than V, decomps. above 300°; chloroplatinate, red, decomps. above 300°, VI (1 g. from 8 g. Et chlorolutidinecarboxylate), yellowish, m. 100-1°; HCl salt, red, m. 221°. VII, obtained in 10% yield through the Ag salt, brown, m. 184°; HCl salt, brown, m. 282°. VIII, m. 67°, sol. in salt. with yellow-red color (yield from VII, about 30%); HCl salt, yellowish, m. 243°; chloroplatinate, yellow, decomps. above 300°; semicarbazone, m. 63°; diazotized p-toluidine coupling product, brown, m. 92°, moderately sol. in dil. HCl, dyes wool and mordanted cotton in acid soln. a red-brown.
IT 873389-14-1, [Δ2,2',(3,3')-Bipyrido[4,3-b]thiophene]-3,3'-dione, 4,4',6,6'-tetramethyl-
(and salts)
RN 873389-14-1 CAPLUS
CN [Δ2,2',(3,3')-Bipyrido[4,3-b]thiophene]-3,3'-dione, 4,4',6,6'-tetramethyl- (3CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	113.34	298.55

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-16.50	-16.50

STN INTERNATIONAL LOGOFF AT 06:34:58 ON 08 MAR 2006